NZ711200B2 - Methods and systems for conditioning of particulate crystalline materials - Google Patents
Methods and systems for conditioning of particulate crystalline materials Download PDFInfo
- Publication number
- NZ711200B2 NZ711200B2 NZ711200A NZ71120014A NZ711200B2 NZ 711200 B2 NZ711200 B2 NZ 711200B2 NZ 711200 A NZ711200 A NZ 711200A NZ 71120014 A NZ71120014 A NZ 71120014A NZ 711200 B2 NZ711200 B2 NZ 711200B2
- Authority
- NZ
- New Zealand
- Prior art keywords
- conditioning
- zone
- gas
- micronized
- conditioning gas
- Prior art date
Links
- 230000003750 conditioning Effects 0.000 title claims abstract description 534
- 239000002178 crystalline material Substances 0.000 title claims description 98
- 239000000463 material Substances 0.000 claims abstract description 242
- 239000002245 particle Substances 0.000 claims abstract description 155
- 230000001143 conditioned Effects 0.000 claims abstract description 98
- 238000000034 method Methods 0.000 claims abstract description 90
- 239000000203 mixture Substances 0.000 claims abstract description 33
- 239000007789 gas Substances 0.000 claims description 421
- 239000002904 solvent Substances 0.000 claims description 97
- 238000002156 mixing Methods 0.000 claims description 94
- VPNYRYCIDCJBOM-UHFFFAOYSA-M Glycopyrronium bromide Chemical compound [Br-].C1[N+](C)(C)CCC1OC(=O)C(O)(C=1C=CC=CC=1)C1CCCC1 VPNYRYCIDCJBOM-UHFFFAOYSA-M 0.000 claims description 71
- 229960002462 glycopyrronium bromide Drugs 0.000 claims description 71
- 239000011236 particulate material Substances 0.000 claims description 68
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 55
- 229940015042 Glycopyrrolate Drugs 0.000 claims description 53
- 238000000137 annealing Methods 0.000 claims description 46
- 238000002347 injection Methods 0.000 claims description 28
- 239000007924 injection Substances 0.000 claims description 28
- 229960004436 Budesonide Drugs 0.000 claims description 23
- VOVIALXJUBGFJZ-VXKMTNQYSA-N Budesonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3O[C@@H](CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O VOVIALXJUBGFJZ-VXKMTNQYSA-N 0.000 claims description 23
- 239000003960 organic solvent Substances 0.000 claims description 22
- 239000012159 carrier gas Substances 0.000 claims description 17
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 17
- 239000003125 aqueous solvent Substances 0.000 claims description 14
- 239000006185 dispersion Substances 0.000 claims description 14
- 229910001873 dinitrogen Inorganic materials 0.000 claims description 11
- 238000000926 separation method Methods 0.000 claims description 8
- 239000012530 fluid Substances 0.000 claims description 7
- 239000002195 soluble material Substances 0.000 claims description 4
- 238000002360 preparation method Methods 0.000 abstract description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 59
- 238000009826 distribution Methods 0.000 description 45
- 239000003795 chemical substances by application Substances 0.000 description 36
- -1 anti-infectives Substances 0.000 description 31
- CZMRCDWAGMRECN-UGDNZRGBSA-N D-sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 26
- 229960004793 Sucrose Drugs 0.000 description 26
- CZMRCDWAGMRECN-GDQSFJPYSA-N Sucrose Natural products O([C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1)[C@@]1(CO)[C@H](O)[C@@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-GDQSFJPYSA-N 0.000 description 25
- 239000007788 liquid Substances 0.000 description 25
- 239000005720 sucrose Substances 0.000 description 25
- 150000001875 compounds Chemical class 0.000 description 19
- 239000003246 corticosteroid Substances 0.000 description 19
- 229940005644 glycopyrronium Drugs 0.000 description 18
- WMWTYOKRWGGJOA-CENSZEJFSA-N Fluticasone propionate Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)SCF)(OC(=O)CC)[C@@]2(C)C[C@@H]1O WMWTYOKRWGGJOA-CENSZEJFSA-N 0.000 description 17
- 238000005070 sampling Methods 0.000 description 14
- MGNNYOODZCAHBA-GQKYHHCASA-N Fluticasone Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)SCF)(O)[C@@]2(C)C[C@@H]1O MGNNYOODZCAHBA-GQKYHHCASA-N 0.000 description 13
- 229960002714 fluticasone Drugs 0.000 description 13
- 229960000289 fluticasone propionate Drugs 0.000 description 13
- 239000000843 powder Substances 0.000 description 13
- 230000002776 aggregation Effects 0.000 description 12
- 238000002425 crystallisation Methods 0.000 description 12
- 230000005712 crystallization Effects 0.000 description 12
- 239000011780 sodium chloride Substances 0.000 description 12
- 238000005054 agglomeration Methods 0.000 description 9
- 150000003839 salts Chemical class 0.000 description 9
- NDAUXUAQIAJITI-UHFFFAOYSA-N Salbutamol Chemical compound CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1 NDAUXUAQIAJITI-UHFFFAOYSA-N 0.000 description 8
- CSCPPACGZOOCGX-UHFFFAOYSA-N acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 8
- 238000010586 diagram Methods 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 239000011521 glass Substances 0.000 description 8
- KFZMGEQAYNKOFK-UHFFFAOYSA-N iso-propanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 8
- 238000004519 manufacturing process Methods 0.000 description 8
- 229960002052 salbutamol Drugs 0.000 description 8
- 239000000126 substance Substances 0.000 description 8
- 230000001131 transforming Effects 0.000 description 8
- 238000004458 analytical method Methods 0.000 description 7
- 238000004320 controlled atmosphere Methods 0.000 description 7
- 238000001704 evaporation Methods 0.000 description 7
- 229910001220 stainless steel Inorganic materials 0.000 description 7
- 239000010935 stainless steel Substances 0.000 description 7
- KWGRBVOPPLSCSI-WPRPVWTQSA-N Ephedrine Chemical compound CN[C@@H](C)[C@H](O)C1=CC=CC=C1 KWGRBVOPPLSCSI-WPRPVWTQSA-N 0.000 description 6
- 239000000556 agonist Substances 0.000 description 6
- 238000000635 electron micrograph Methods 0.000 description 6
- 150000002148 esters Chemical class 0.000 description 6
- 230000001747 exhibiting Effects 0.000 description 6
- 238000010902 jet-milling Methods 0.000 description 6
- 238000003801 milling Methods 0.000 description 6
- 239000003149 muscarinic antagonist Substances 0.000 description 6
- 230000003287 optical Effects 0.000 description 6
- 239000000825 pharmaceutical preparation Substances 0.000 description 6
- 230000002685 pulmonary Effects 0.000 description 6
- LMOINURANNBYCM-UHFFFAOYSA-N Orciprenaline Chemical compound CC(C)NCC(O)C1=CC(O)=CC(O)=C1 LMOINURANNBYCM-UHFFFAOYSA-N 0.000 description 5
- 238000004108 freeze drying Methods 0.000 description 5
- 238000000227 grinding Methods 0.000 description 5
- 150000002500 ions Chemical class 0.000 description 5
- 229960002657 orciprenaline Drugs 0.000 description 5
- JWZZKOKVBUJMES-UHFFFAOYSA-N 4-{1-hydroxy-2-[(propan-2-yl)amino]ethyl}benzene-1,2-diol Chemical compound CC(C)NCC(O)C1=CC=C(O)C(O)=C1 JWZZKOKVBUJMES-UHFFFAOYSA-N 0.000 description 4
- 229940023808 Albuterol Drugs 0.000 description 4
- XWTYSIMOBUGWOL-UHFFFAOYSA-N Bricaril Chemical compound CC(C)(C)NCC(O)C1=CC(O)=CC(O)=C1 XWTYSIMOBUGWOL-UHFFFAOYSA-N 0.000 description 4
- LSLYOANBFKQKPT-UHFFFAOYSA-N Fenoterol Chemical compound C=1C(O)=CC(O)=CC=1C(O)CNC(C)CC1=CC=C(O)C=C1 LSLYOANBFKQKPT-UHFFFAOYSA-N 0.000 description 4
- BPZSYCZIITTYBL-YJYMSZOUSA-N Formoterol Chemical compound C1=CC(OC)=CC=C1C[C@@H](C)NC[C@H](O)C1=CC=C(O)C(NC=O)=C1 BPZSYCZIITTYBL-YJYMSZOUSA-N 0.000 description 4
- BKIMMITUMNQMOS-UHFFFAOYSA-N Nonane Chemical compound CCCCCCCCC BKIMMITUMNQMOS-UHFFFAOYSA-N 0.000 description 4
- GIIZNNXWQWCKIB-UHFFFAOYSA-N Serevent Chemical compound C1=C(O)C(CO)=CC(C(O)CNCCCCCCOCCCCC=2C=CC=CC=2)=C1 GIIZNNXWQWCKIB-UHFFFAOYSA-N 0.000 description 4
- 229960000195 Terbutaline Drugs 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 229960001022 fenoterol Drugs 0.000 description 4
- 229960002848 formoterol Drugs 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 238000010438 heat treatment Methods 0.000 description 4
- 239000011261 inert gas Substances 0.000 description 4
- 229960001317 isoprenaline Drugs 0.000 description 4
- 229940054556 metaproterenol Drugs 0.000 description 4
- AFVFQIVMOAPDHO-UHFFFAOYSA-N methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 4
- OKKJLVBELUTLKV-UHFFFAOYSA-N methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 4
- KBPLFHHGFOOTCA-UHFFFAOYSA-N octanol Chemical compound CCCCCCCCO KBPLFHHGFOOTCA-UHFFFAOYSA-N 0.000 description 4
- 229960004017 salmeterol Drugs 0.000 description 4
- 230000001225 therapeutic Effects 0.000 description 4
- BKLAJZNVMHLXAP-VKGMXUHCSA-N 3-[(1R,5S)-8,8-dimethyl-8-azoniabicyclo[3.2.1]octan-3-yl]-2,2-diphenylpropanenitrile Chemical compound C([C@H]1CC[C@@H](C2)[N+]1(C)C)C2CC(C#N)(C=1C=CC=CC=1)C1=CC=CC=C1 BKLAJZNVMHLXAP-VKGMXUHCSA-N 0.000 description 3
- 229930006677 A03BA01 - Atropine Natural products 0.000 description 3
- 229930000680 A04AD01 - Scopolamine Natural products 0.000 description 3
- RKUNBYITZUJHSG-SPUOUPEWSA-N Atropine Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)N2C)C(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-SPUOUPEWSA-N 0.000 description 3
- 229960000396 Atropine Drugs 0.000 description 3
- NVOYVOBDTVTBDX-PMEUIYRNSA-N CC[N+]1(C)[C@H]2C[C@@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)[C@H](CO)C1=CC=CC=C1 Chemical compound CC[N+]1(C)[C@H]2C[C@@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)[C@H](CO)C1=CC=CC=C1 NVOYVOBDTVTBDX-PMEUIYRNSA-N 0.000 description 3
- OYYDSUSKLWTMMQ-JKHIJQBDSA-N CHEMBL1888176 Chemical compound [N+]12([C@@H]3CC[C@H]2C[C@H](C3)OC(=O)C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CCCC1 OYYDSUSKLWTMMQ-JKHIJQBDSA-N 0.000 description 3
- LUKZNWIVRBCLON-GXOBDPJESA-N Ciclesonide Chemical compound C1([C@H]2O[C@@]3([C@H](O2)C[C@@H]2[C@@]3(C[C@H](O)[C@@H]3[C@@]4(C)C=CC(=O)C=C4CC[C@H]32)C)C(=O)COC(=O)C(C)C)CCCCC1 LUKZNWIVRBCLON-GXOBDPJESA-N 0.000 description 3
- 229940064701 Corticosteroid nasal preparations for topical use Drugs 0.000 description 3
- 229960001334 Corticosteroids Drugs 0.000 description 3
- MZDOIJOUFRQXHC-UHFFFAOYSA-N Dimenhydrinate Chemical compound O=C1N(C)C(=O)N(C)C2=NC(Cl)=N[C]21.C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 MZDOIJOUFRQXHC-UHFFFAOYSA-N 0.000 description 3
- 229960004993 Dimenhydrinate Drugs 0.000 description 3
- STECJAGHUSJQJN-GAUPFVANSA-N Hyoscine Natural products C1([C@H](CO)C(=O)OC2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-GAUPFVANSA-N 0.000 description 3
- 229960001664 Mometasone Drugs 0.000 description 3
- STECJAGHUSJQJN-FWXGHANASA-N Scopolamine Chemical compound C1([C@@H](CO)C(=O)O[C@H]2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-FWXGHANASA-N 0.000 description 3
- DQHNAVOVODVIMG-UHFFFAOYSA-M Tiotropium bromide Chemical compound [Br-].C1C(C2C3O2)[N+](C)(C)C3CC1OC(=O)C(O)(C=1SC=CC=1)C1=CC=CS1 DQHNAVOVODVIMG-UHFFFAOYSA-M 0.000 description 3
- BGDKAVGWHJFAGW-UHFFFAOYSA-N Tropicamide Chemical compound C=1C=CC=CC=1C(CO)C(=O)N(CC)CC1=CC=NC=C1 BGDKAVGWHJFAGW-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N acetic acid ethyl ester Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- ASMXXROZKSBQIH-VITNCHFBSA-N aclidinium Chemical compound C([C@@H](C(CC1)CC2)OC(=O)C(O)(C=3SC=CC=3)C=3SC=CC=3)[N+]21CCCOC1=CC=CC=C1 ASMXXROZKSBQIH-VITNCHFBSA-N 0.000 description 3
- 229940019903 aclidinium Drugs 0.000 description 3
- 239000008186 active pharmaceutical agent Substances 0.000 description 3
- 238000007792 addition Methods 0.000 description 3
- UCTWMZQNUQWSLP-UHFFFAOYSA-N adrenaline Chemical compound CNCC(O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-UHFFFAOYSA-N 0.000 description 3
- 238000004220 aggregation Methods 0.000 description 3
- 229910052783 alkali metal Inorganic materials 0.000 description 3
- 150000001340 alkali metals Chemical class 0.000 description 3
- 239000012298 atmosphere Substances 0.000 description 3
- CPELXLSAUQHCOX-UHFFFAOYSA-M bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 3
- 150000003842 bromide salts Chemical class 0.000 description 3
- 229960003728 ciclesonide Drugs 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 230000001276 controlling effect Effects 0.000 description 3
- 238000004090 dissolution Methods 0.000 description 3
- 229940079593 drugs Drugs 0.000 description 3
- 229960002179 ephedrine Drugs 0.000 description 3
- 150000004677 hydrates Chemical class 0.000 description 3
- 150000002576 ketones Chemical class 0.000 description 3
- QLIIKPVHVRXHRI-CXSFZGCWSA-N mometasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CCl)(O)[C@@]1(C)C[C@@H]2O QLIIKPVHVRXHRI-CXSFZGCWSA-N 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- 235000016709 nutrition Nutrition 0.000 description 3
- 229960000797 oxitropium Drugs 0.000 description 3
- 238000004806 packaging method and process Methods 0.000 description 3
- 239000000546 pharmaceutic aid Substances 0.000 description 3
- 239000008194 pharmaceutical composition Substances 0.000 description 3
- 238000001953 recrystallisation Methods 0.000 description 3
- 238000001878 scanning electron micrograph Methods 0.000 description 3
- 229960002646 scopolamine Drugs 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 238000001694 spray drying Methods 0.000 description 3
- 229940110309 tiotropium Drugs 0.000 description 3
- 229940083878 topical for treatment of hemorrhoids and anal fissures Corticosteroids Drugs 0.000 description 3
- 229960004791 tropicamide Drugs 0.000 description 3
- 229960001491 trospium Drugs 0.000 description 3
- 238000009834 vaporization Methods 0.000 description 3
- 230000004580 weight loss Effects 0.000 description 3
- FDPIMTJIUBPUKL-UHFFFAOYSA-N 3-Pentanone Chemical compound CCC(=O)CC FDPIMTJIUBPUKL-UHFFFAOYSA-N 0.000 description 2
- CQFNOACVVKSEOJ-VBQPQCOESA-N Bronilide Chemical compound O.C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O CQFNOACVVKSEOJ-VBQPQCOESA-N 0.000 description 2
- BJHIKXHVCXFQLS-UYFOZJQFSA-N Fructose Natural products OC[C@@H](O)[C@@H](O)[C@H](O)C(=O)CO BJHIKXHVCXFQLS-UYFOZJQFSA-N 0.000 description 2
- GUBGYTABKSRVRQ-YOLKTULGSA-N Maltose Natural products O([C@@H]1[C@H](O)[C@@H](O)[C@H](O)O[C@H]1CO)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 GUBGYTABKSRVRQ-YOLKTULGSA-N 0.000 description 2
- TVMXDCGIABBOFY-UHFFFAOYSA-N Octane Chemical compound CCCCCCCC TVMXDCGIABBOFY-UHFFFAOYSA-N 0.000 description 2
- RMHMFHUVIITRHF-UHFFFAOYSA-N Pirenzepine Chemical compound C1CN(C)CCN1CC(=O)N1C2=NC=CC=C2NC(=O)C2=CC=CC=C21 RMHMFHUVIITRHF-UHFFFAOYSA-N 0.000 description 2
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N Prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 2
- PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 2
- 229940035295 Ting Drugs 0.000 description 2
- SRBFZHDQGSBBOR-SQOUGZDYSA-N Xylose Natural products O[C@@H]1CO[C@@H](O)[C@@H](O)[C@@H]1O SRBFZHDQGSBBOR-SQOUGZDYSA-N 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 230000000240 adjuvant Effects 0.000 description 2
- 239000000443 aerosol Substances 0.000 description 2
- 239000003570 air Substances 0.000 description 2
- 150000001335 aliphatic alkanes Chemical class 0.000 description 2
- 230000003110 anti-inflammatory Effects 0.000 description 2
- 239000002260 anti-inflammatory agent Substances 0.000 description 2
- XKRFYHLGVUSROY-UHFFFAOYSA-N argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000002537 cosmetic Substances 0.000 description 2
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 125000000031 ethylamino group Chemical group [H]C([H])([H])C([H])([H])N([H])[*] 0.000 description 2
- 229960000676 flunisolide Drugs 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 235000013373 food additive Nutrition 0.000 description 2
- 239000001307 helium Substances 0.000 description 2
- 229910052734 helium Inorganic materials 0.000 description 2
- SWQJXJOGLNCZEY-UHFFFAOYSA-N helium(0) Chemical compound [He] SWQJXJOGLNCZEY-UHFFFAOYSA-N 0.000 description 2
- 238000003384 imaging method Methods 0.000 description 2
- SIKJAQJRHWYJAI-UHFFFAOYSA-N indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 2
- 229940098779 methanesulfonic acid Drugs 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 125000001820 oxy group Chemical group [*:1]O[*:2] 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 2
- 229960004633 pirenzepine Drugs 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 229960004618 prednisone Drugs 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-M propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 239000000018 receptor agonist Substances 0.000 description 2
- 230000000241 respiratory Effects 0.000 description 2
- 230000000717 retained Effects 0.000 description 2
- 239000012453 solvate Substances 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- FVTWTVQXNAJTQP-KRKINAOUSA-N umeclidinium Chemical compound C=1C=CC=CC=1C([C@@]12CC[N@@+](CCOCC=3C=CC=CC=3)(CC1)CC2)(O)C1=CC=CC=C1 FVTWTVQXNAJTQP-KRKINAOUSA-N 0.000 description 2
- 229960004258 umeclidinium Drugs 0.000 description 2
- BAQAVOSOZGMPRM-JVFSCRHWSA-N (2R,3R,4R,5R,6R)-2-[(2S,3R,4R,5R)-2,5-bis(chloromethyl)-3,4-dihydroxyoxolan-2-yl]oxy-5-chloro-6-(hydroxymethyl)oxane-3,4-diol Chemical compound O[C@@H]1[C@@H](O)[C@@H](Cl)[C@@H](CO)O[C@@H]1O[C@]1(CCl)[C@H](O)[C@@H](O)[C@H](CCl)O1 BAQAVOSOZGMPRM-JVFSCRHWSA-N 0.000 description 1
- DCYGAPKNVCQNOE-UHFFFAOYSA-M 2,2,2-triphenylacetate Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)(C(=O)[O-])C1=CC=CC=C1 DCYGAPKNVCQNOE-UHFFFAOYSA-M 0.000 description 1
- PYHXGXCGESYPCW-UHFFFAOYSA-M 2,2-diphenylacetate Chemical compound C=1C=CC=CC=1C(C(=O)[O-])C1=CC=CC=C1 PYHXGXCGESYPCW-UHFFFAOYSA-M 0.000 description 1
- ALKYHXVLJMQRLQ-UHFFFAOYSA-M 3-carboxynaphthalen-2-olate Chemical compound C1=CC=C2C=C(C([O-])=O)C(O)=CC2=C1 ALKYHXVLJMQRLQ-UHFFFAOYSA-M 0.000 description 1
- XRHGYUZYPHTUJZ-UHFFFAOYSA-M 4-chlorobenzoate Chemical compound [O-]C(=O)C1=CC=C(Cl)C=C1 XRHGYUZYPHTUJZ-UHFFFAOYSA-M 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-M 4-hydroxybenzoate Chemical compound OC1=CC=C(C([O-])=O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-M 0.000 description 1
- IHOXNOQMRZISPV-YJYMSZOUSA-N 5-[(1R)-1-hydroxy-2-[[(2R)-1-(4-methoxyphenyl)propan-2-yl]azaniumyl]ethyl]-2-oxo-1H-quinolin-8-olate Chemical compound C1=CC(OC)=CC=C1C[C@@H](C)NC[C@H](O)C1=CC=C(O)C2=C1C=CC(=O)N2 IHOXNOQMRZISPV-YJYMSZOUSA-N 0.000 description 1
- 229940035676 ANALGESICS Drugs 0.000 description 1
- 229940074728 ANTIINFECTIVE OPHTHALMOLOGICS Drugs 0.000 description 1
- 229940021383 Antiinfective irrigating solutions Drugs 0.000 description 1
- 229960005475 Antiinfectives Drugs 0.000 description 1
- UIQMVEYFGZJHCZ-SSTWWWIQSA-N Antorphin Chemical compound C([C@@H](N(CC1)CC=C)[C@@H]2C=C[C@@H]3O)C4=CC=C(O)C5=C4[C@@]21[C@H]3O5 UIQMVEYFGZJHCZ-SSTWWWIQSA-N 0.000 description 1
- ANZXOIAKUNOVQU-UHFFFAOYSA-N Bambuterol Chemical compound CN(C)C(=O)OC1=CC(OC(=O)N(C)C)=CC(C(O)CNC(C)(C)C)=C1 ANZXOIAKUNOVQU-UHFFFAOYSA-N 0.000 description 1
- KUVIULQEHSCUHY-XYWKZLDCSA-N Beclometasone dipropionate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)COC(=O)CC)(OC(=O)CC)[C@@]1(C)C[C@@H]2O KUVIULQEHSCUHY-XYWKZLDCSA-N 0.000 description 1
- 229940092705 Beclomethasone Drugs 0.000 description 1
- 229940092703 Beclomethasone Dipropionate Drugs 0.000 description 1
- UREBDLICKHMUKA-DVTGEIKXSA-N Betamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-DVTGEIKXSA-N 0.000 description 1
- 230000036912 Bioavailability Effects 0.000 description 1
- FZGVEKPRDOIXJY-UHFFFAOYSA-N Bitolterol Chemical compound C1=CC(C)=CC=C1C(=O)OC1=CC=C(C(O)CNC(C)(C)C)C=C1OC(=O)C1=CC=C(C)C=C1 FZGVEKPRDOIXJY-UHFFFAOYSA-N 0.000 description 1
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 1
- KEMXXQOFIRIICG-UHFFFAOYSA-N Carbuterol Chemical compound CC(C)(C)NCC(O)C1=CC=C(O)C(NC(N)=O)=C1 KEMXXQOFIRIICG-UHFFFAOYSA-N 0.000 description 1
- 229950010713 Carmoterol Drugs 0.000 description 1
- STJMRWALKKWQGH-UHFFFAOYSA-N Clenbuterol Chemical compound CC(C)(C)NCC(O)C1=CC(Cl)=C(N)C(Cl)=C1 STJMRWALKKWQGH-UHFFFAOYSA-N 0.000 description 1
- MFYSYFVPBJMHGN-ZPOLXVRWSA-N Cortisone Chemical compound O=C1CC[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 MFYSYFVPBJMHGN-ZPOLXVRWSA-N 0.000 description 1
- 229960003624 Creatine Drugs 0.000 description 1
- 229940109275 Cyclamate Drugs 0.000 description 1
- GZCGUPFRVQAUEE-KCDKBNATSA-N D-(+)-Galactose Natural products OC[C@@H](O)[C@H](O)[C@H](O)[C@@H](O)C=O GZCGUPFRVQAUEE-KCDKBNATSA-N 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N D-Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- FBPFZTCFMRRESA-KAZBKCHUSA-N D-Mannitol Natural products OC[C@@H](O)[C@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KAZBKCHUSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
- 229940030606 DIURETICS Drugs 0.000 description 1
- 229960003957 Dexamethasone Drugs 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N Dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- 229920002456 HOTAIR Polymers 0.000 description 1
- OXLZNBCNGJWPRV-UHFFFAOYSA-N Hexoprenaline Chemical compound C=1C=C(O)C(O)=CC=1C(O)CNCCCCCCNCC(O)C1=CC=C(O)C(O)=C1 OXLZNBCNGJWPRV-UHFFFAOYSA-N 0.000 description 1
- QZZUEBNBZAPZLX-QFIPXVFZSA-N Indacaterol Chemical compound N1C(=O)C=CC2=C1C(O)=CC=C2[C@@H](O)CNC1CC(C=C(C(=C2)CC)CC)=C2C1 QZZUEBNBZAPZLX-QFIPXVFZSA-N 0.000 description 1
- 229960001888 Ipratropium Drugs 0.000 description 1
- HPIGCVXMBGOWTF-UHFFFAOYSA-N Isomaltol Chemical compound CC(=O)C=1OC=CC=1O HPIGCVXMBGOWTF-UHFFFAOYSA-N 0.000 description 1
- 229940039009 Isoproterenol Drugs 0.000 description 1
- TYQCGQRIZGCHNB-JLAZNSOCSA-N L-ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(O)=C(O)C1=O TYQCGQRIZGCHNB-JLAZNSOCSA-N 0.000 description 1
- NDAUXUAQIAJITI-LBPRGKRZSA-N Levosalbutamol Chemical compound CC(C)(C)NC[C@H](O)C1=CC=C(O)C(CO)=C1 NDAUXUAQIAJITI-LBPRGKRZSA-N 0.000 description 1
- 239000005913 Maltodextrin Substances 0.000 description 1
- 229920002774 Maltodextrin Polymers 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FEWJPZIEWOKRBE-XIXRPRMCSA-N Mesotartaric acid Chemical compound OC(=O)[C@@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-XIXRPRMCSA-N 0.000 description 1
- VHRSUDSXCMQTMA-PJHHCJLFSA-N Methylprednisolone Chemical compound C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)CO)CC[C@H]21 VHRSUDSXCMQTMA-PJHHCJLFSA-N 0.000 description 1
- 229950001768 Milveterol Drugs 0.000 description 1
- BMKINZUHKYLSKI-DQEYMECFSA-N N-[2-hydroxy-5-[(1R)-1-hydroxy-2-[2-[4-[[(2R)-2-hydroxy-2-phenylethyl]amino]phenyl]ethylamino]ethyl]phenyl]formamide Chemical compound C1([C@@H](O)CNC2=CC=C(C=C2)CCNC[C@H](O)C=2C=C(NC=O)C(O)=CC=2)=CC=CC=C1 BMKINZUHKYLSKI-DQEYMECFSA-N 0.000 description 1
- AKNNEGZIBPJZJG-MSOLQXFVSA-N Noscapine Chemical compound CN1CCC2=CC=3OCOC=3C(OC)=C2[C@@H]1[C@@H]1C2=CC=C(OC)C(OC)=C2C(=O)O1 AKNNEGZIBPJZJG-MSOLQXFVSA-N 0.000 description 1
- 229960004708 Noscapine Drugs 0.000 description 1
- 229960002288 Procaterol Drugs 0.000 description 1
- FKNXQNWAXFXVNW-BLLLJJGKSA-N Procaterol Chemical compound N1C(=O)C=CC2=C1C(O)=CC=C2[C@@H](O)[C@@H](NC(C)C)CC FKNXQNWAXFXVNW-BLLLJJGKSA-N 0.000 description 1
- WVLAAKXASPCBGT-UHFFFAOYSA-N Reproterol Chemical compound C1=2C(=O)N(C)C(=O)N(C)C=2N=CN1CCCNCC(O)C1=CC(O)=CC(O)=C1 WVLAAKXASPCBGT-UHFFFAOYSA-N 0.000 description 1
- IYMMESGOJVNCKV-SKDRFNHKSA-N Rimiterol Chemical compound C([C@@H]1[C@@H](O)C=2C=C(O)C(O)=CC=2)CCCN1 IYMMESGOJVNCKV-SKDRFNHKSA-N 0.000 description 1
- UDIPTWFVPPPURJ-UHFFFAOYSA-M Sodium cyclamate Chemical compound [Na+].[O-]S(=O)(=O)NC1CCCCC1 UDIPTWFVPPPURJ-UHFFFAOYSA-M 0.000 description 1
- 240000001132 Stevia rebaudiana Species 0.000 description 1
- 239000004376 Sucralose Substances 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N Trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- 229960002117 Triamcinolone Acetonide Drugs 0.000 description 1
- YNDXUCZADRHECN-JNQJZLCISA-N Triamcinolone acetonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O YNDXUCZADRHECN-JNQJZLCISA-N 0.000 description 1
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 description 1
- 229940029983 VITAMINS Drugs 0.000 description 1
- 229940021016 Vitamin IV solution additives Drugs 0.000 description 1
- 229960003487 Xylose Drugs 0.000 description 1
- ASCUXPQGEXGEMJ-GPLGTHOPSA-N [(2R,3S,4S,5R,6S)-3,4,5-triacetyloxy-6-[[(2R,3R,4S,5R,6R)-3,4,5-triacetyloxy-6-(4-methylanilino)oxan-2-yl]methoxy]oxan-2-yl]methyl acetate Chemical compound CC(=O)O[C@@H]1[C@@H](OC(C)=O)[C@@H](OC(C)=O)[C@@H](COC(=O)C)O[C@@H]1OC[C@@H]1[C@@H](OC(C)=O)[C@H](OC(C)=O)[C@@H](OC(C)=O)[C@H](NC=2C=CC(C)=CC=2)O1 ASCUXPQGEXGEMJ-GPLGTHOPSA-N 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K [O-]P([O-])([O-])=O Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 230000001154 acute Effects 0.000 description 1
- 125000005073 adamantyl group Chemical group C12(CC3CC(CC(C1)C3)C2)* 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000000202 analgesic Effects 0.000 description 1
- 230000000954 anitussive Effects 0.000 description 1
- 230000003042 antagnostic Effects 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 230000001396 anti-anti-diuretic Effects 0.000 description 1
- 230000002924 anti-infective Effects 0.000 description 1
- 239000003434 antitussive agent Substances 0.000 description 1
- 150000001479 arabinose derivatives Chemical class 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 238000000889 atomisation Methods 0.000 description 1
- 229960003060 bambuterol Drugs 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 238000010923 batch production Methods 0.000 description 1
- 229950000210 beclometasone dipropionate Drugs 0.000 description 1
- NBMKJKDGKREAPL-DVTGEIKXSA-N beclomethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O NBMKJKDGKREAPL-DVTGEIKXSA-N 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- 229940077388 benzenesulfonate Drugs 0.000 description 1
- 239000002876 beta blocker Substances 0.000 description 1
- 229960002537 betamethasone Drugs 0.000 description 1
- 230000035514 bioavailability Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229960004620 bitolterol Drugs 0.000 description 1
- 230000003182 bronchodilatating Effects 0.000 description 1
- 239000000168 bronchodilator agent Substances 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-M butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 1
- CURLTUGMZLYLDI-UHFFFAOYSA-N carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 229960001386 carbuterol Drugs 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 229960001117 clenbuterol Drugs 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 238000010924 continuous production Methods 0.000 description 1
- 230000000875 corresponding Effects 0.000 description 1
- 229960004544 cortisone Drugs 0.000 description 1
- 239000006046 creatine Substances 0.000 description 1
- CVSVTCORWBXHQV-UHFFFAOYSA-N creatine zwitterion Chemical compound NC(=[NH2+])N(C)CC([O-])=O CVSVTCORWBXHQV-UHFFFAOYSA-N 0.000 description 1
- 230000004059 degradation Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 235000013681 dietary sucrose Nutrition 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- KRHYYFGTRYWZRS-UHFFFAOYSA-M fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 238000004817 gas chromatography Methods 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229960000708 hexoprenaline Drugs 0.000 description 1
- 230000001632 homeopathic Effects 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 1
- 229960004078 indacaterol Drugs 0.000 description 1
- 239000003317 industrial substance Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-M iodide Chemical compound [I-] XMBWDFGMSWQBCA-UHFFFAOYSA-M 0.000 description 1
- OEXHQOGQTVQTAT-JRNQLAHRSA-N ipratropium Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)[N@@+]2(C)C(C)C)C(=O)C(CO)C1=CC=CC=C1 OEXHQOGQTVQTAT-JRNQLAHRSA-N 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- BJHIKXHVCXFQLS-PYWDMBMJSA-N keto-D-sorbose Chemical compound OC[C@@H](O)[C@H](O)[C@@H](O)C(=O)CO BJHIKXHVCXFQLS-PYWDMBMJSA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 229950008204 levosalbutamol Drugs 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-L maleate(2-) Chemical compound [O-]C(=O)\C=C/C([O-])=O VZCYOOQTPOCHFL-UPHRSURJSA-L 0.000 description 1
- 229940035034 maltodextrin Drugs 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-M methanesulfonate Chemical compound CS([O-])(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-M 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-M methanoate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
- 229960004584 methylprednisolone Drugs 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 230000000051 modifying Effects 0.000 description 1
- 229930014621 narcotine Natural products 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- 239000002417 nutraceutical Substances 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- MYMOFIZGZYHOMD-UHFFFAOYSA-N oxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- RZVAJINKPMORJF-UHFFFAOYSA-N p-acetaminophenol Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000002587 phosphodiesterase IV inhibitor Substances 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- DNIAPMSPPWPWGF-UHFFFAOYSA-N propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 1
- 238000010926 purge Methods 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 230000003134 recirculating Effects 0.000 description 1
- 229960002720 reproterol Drugs 0.000 description 1
- 229960001457 rimiterol Drugs 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
- 238000010008 shearing Methods 0.000 description 1
- 230000003381 solubilizing Effects 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 230000003637 steroidlike Effects 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 229940086735 succinate Drugs 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 235000019408 sucralose Nutrition 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000002194 synthesizing Effects 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229930003231 vitamins Natural products 0.000 description 1
- 238000001238 wet grinding Methods 0.000 description 1
- WQZGKKKJIJFFOK-PHYPRBDBSA-N α-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N β-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/537—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines spiro-condensed or forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7016—Disaccharides, e.g. lactose, lactulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B02—CRUSHING, PULVERISING, OR DISINTEGRATING; PREPARATORY TREATMENT OF GRAIN FOR MILLING
- B02C—CRUSHING, PULVERISING, OR DISINTEGRATING IN GENERAL; MILLING GRAIN
- B02C19/00—Other disintegrating devices or methods
- B02C19/06—Jet mills
Abstract
Methods and systems for the preparation of conditioned micronized active agents. Additionally, methods and systems for in-process conditioning of micronized active agent particles and compositions comprising conditioned micronized materials.
Description
METHODS AND SYSTEMS FOR CONDITIONING OF
PARTICULATE CRYSTALLINE MATERIALS
BACKGROUND
Technical Field
This disclosure relates generally to systems and methods for the
preparation and stabilization of particulate materials. More specifically, this
disclosure relates to systems and methods for conditioning particulate materials
to improve the physicochemical stability of the materials as well as
compositions orating such les.
Description of the Related Art
Particulate crystalline materials, including micronized crystalline
particulates, are useful in a variety of contexts. For example, certain industrially
useful compounds are conveniently stored in bulk as dry, particulate powders.
Additionally, certain compounds can be better utilized or orated into
commercial products when provided as micronized lline particulates. This
can be seen with pharmaceutically active compounds that exhibit improved
formulation, delivery, or therapeutic utes when ed in micronized
crystalline form.
However, processes used to produce certain crystalline materials
can result in material characteristics that introduce an undesired level of
physiochemical ility. Techniques for micronization of crystalline material
often e energy-intensive milling, grinding, shearing or particle-to-particle
collisions to reduce le size. An example of one such technique is air jet
milling, which uses high velocity air or gas to cause particle-to-particle collisions
and to generate micronized material, including particles ranging from about 0.5
to about 30 pm in diameter. The exertion of thermal or mechanical energy
during -intensive ization processes can cause the ion of
non-crystalline, amorphous material that can lead to significant physicochemical
instability of the resulting micronized particles. Such amorphous al may
be present in the form of amorphous regions on otherwise crystalline particles
or as substantially amorphous particles.
The presence of amorphous material within micronized crystalline
material can result in a sity for the particles to fuse, aggregate, and/or
agglomerate. In certain cases, the instability appears particularly acute when
the ized material is exposed, even for very short periods of time, to an
environment that includes a solvent e of solubilizing or plasticizing the
amorphous material. In such instances, exposure of the micronized material
often leads to recrystallization of amorphous material ned therein or
sorbed, vapor-driven conversion of amorphous phase to crystalline phase,
which can be accompanied by fusing and agglomeration of the ized
particles. The fusing, aggregation and/or agglomeration of the micronized
les can cause significant s in particle size and the overall particle
size distribution of the micronized material, which is problematic for applications
requiring the long-term physical stability of the micronized material.
In addition, processes used in the manufacture and purification of
crystalline materials can leave undesired contaminants. For e, solvents,
ing various organic solvents, play an important role in the manufacture of
pharmaceutically active nds and ents used in the production of
drug products. Solvents are often used during the synthesis of
ceutically active compounds and drug product excipients to increase
yields or aid in crystallization. In many manufacturing processes, the final
purification step involves crystallization or re-crystallization of the desired
compound, and the crystalline material formed in such processes can entrap
solvent present in the solution from which the material is crystallized. Even
after subjecting the material to a drying step, such as a freeze-drying or a high
temperature drying process, solvent ped in a crystalline material is often
difficult to completely remove, and some amount of residual solvent can remain.
The presence of residual solvent, even in small amount can have undesirable
WO 44894
effects. Organic solvents, in ular, can present health and safety hazards
and can influence product efficacy, safety and stability.
BRIEF DESCRIPTION OF THE SEVERAL VIEWS OF THE GS
Figure 1 is a diagram showing one ment of a system
sed herein for in-process conditioning of micronized crystalline material.
Figure 2 is a diagram showing an embodiment of a system
disclosed herein for in-process conditioning of micronized crystalline material.
Figure 3A is a drawing of one view of one embodiment of a
sion head assembly as described in the present disclosure.
Figure 3B is a drawing of another view of one embodiment of a
dispersion head assembly as described in the present sure.
Figure 3C is a drawing of a sectional view of one
embodiment of a sion head assembly.
Figure 4A is a cross-sectional drawing of one embodiment of a
mixing head as described in the present disclosure.
Figure 4B is a cross-sectional drawing of another embodiment of
a mixing head as described in the present disclosure.
Figure 5 is a graph ing the unstable particle size distribution
of a standard micronized glycopyrrolate sample as discussed in Example 1.
Figure 6A is an electron micrograph showing the amorphous
morphology of a standard micronized glycopyrrolate sample as discussed in
Example 1.
Figure 6B is an electron micrograph showing the fusing and
eration of a standard micronized glycopyrrolate sample after exposure
as discussed in Example 1.
Figure 7 is a graph depicting the stable particle size distribution of
a conditioned micronized glycopyrrolate sample as discussed in Example 1.
Figure 8A is an electron micrograph showing the crystalline
morphology of a conditioned micronized glycopyrrolate sample as discussed in
Example 1.
Figure 8B is an electron micrograph showing the increased
stability of a conditioned ized yrrolate sample after exposure as
discussed in Example 1.
Figure 9 provides the ethanol vapor sorption isotherm at 250C for
micronized budesonide materials prepared in Example 2.
Figure 10 includes SEM micrographs of micronized budesonide
materials prepared in Example 2.
Figure 11 provides the ethanol vapor sorption isotherm at 250C for
micronized fluticasone propionate materials prepared in Example 3.
Figure 12 es SEM micrographs of micronized fluticasone
materials prepared in Example 3.
Figure 13 provides the water vapor sorption isotherm at 250C for
micronized e materials prepared in e 4.
Figure 14 includes SEM micrographs of micronized sucrose
materials prepared in Example 4.
Figure 15 provides a graph illustrating the particle size bution
of micronized, conditioned sucrose material prepared in Example 4.
Figure 16 illustrates an exemplary plasticization curve, which
shows the Tg of a given amorphous al as a function of solvent t.
Figure 17 illustrates an exemplary sorption isotherm, representing
the amount of solvent in an amorphous material as a function of the solvent
activity at a given temperature.
Figure 18 illustrates an exemplary stability diagram for
glycopyrrolate.
Figure 19 is a diagram showing an embodiment of a system
disclosed herein configured to tate multiple ioning steps.
Figure 20 is a diagram showing r embodiment of a system
disclosed herein configured to facilitate multiple conditioning steps.
2014/029489
DETAILED DESCRIPTION
Systems and methods for conditioning particulate crystalline
material are described herein. ioning a particulate crystalline material
according to the present description generally involves (i) providing a particulate
material to be conditioned, (ii) delivering the material to be conditioned to a
mixing zone where it is combined with a conditioning gas, (iii) maintaining the
material in contact with the conditioning gas within a conditioning zone for a
d residence time, (iv) separating the conditioned material from the
conditioning gas, and (v) collecting the conditioned material. In carrying out a
conditioning s according to the present description, the al to be
conditioned is lly entrained or aerosolized within a delivery gas that is
blended with the conditioning gas, and the particulate material remains
entrained, suspended or aerosolized in the conditioning gas as it travels
through the conditioning zone. The nature of the conditioning gas and the
residence time of the particulate al within the conditioning zone are
lled to accomplish annealing or phase transformation of the material.
In n embodiments, the systems and methods described
herein may be adapted for conditioning a single crystalline al. In
alternative embodiments, the systems and methods described herein may be
adapted to simultaneously ion two or more crystalline materials. For
example, where two or more materials are to be ioned simultaneously,
the materials may be introduced into a conditioning zone as a blended material
or as individual materials delivered via independent material inputs.
Additionally, the systems and methods described herein can be
configured and adapted to provide one or more ioning steps. For
example, in certain ments, systems and methods may be d to
provide a conditioning gas and conditioning zone that subject the particulate
material to annealing conditions whereby amorphous material is converted into
a more stable crystalline structure, and the amorphous content of the of the
crystalline material is measurably reduced or eliminated. In other
embodiments, the systems and methods described herein may be adapted to
anneal particulate crystalline material by reducing the ce of residual
solvent(s). In such embodiments, the systems and methods may be adapted to
provide a conditioning gas and conditioning zone that subject the particulate
material to annealing conditions y residual solvent within the crystalline
al is reduced, removed, or replaced by, for example, vaporization or by
solvent exchange. In still other embodiments, the methods and systems
described herein can be adapted to both reduce or ate amorphous
content and reduce or eliminate the ce of residual t(s). In such
embodiments, the different annealing ses may be conducted
simultaneously (e.g., using a conditioning gas and conditioning zone that
serves to reduce both amorphous content and the presence of one or more
solvent within the crystalline material) or sequentially using primary and
secondary conditioning environments.
Where the systems and methods described herein are adapted to
reduce amorphous content, without being bound by a particular theory, it is
presently believed that amorphous material present in the crystalline ulate
material oes an amorphous to crystalline phase transformation preceded
by the plasticization or zed dissolution followed by llization of the
amorphous material. Annealing of particulate material, including micronized
material, as described herein works to reduce the amount of amorphous
al and preserve the desired particle size distribution of the particulate
material by inhibiting fusing, aggregation, and/or agglomeration of the
micronized particles as a result of the plasticization or localized dissolution that
can occur in unannealed materials. In specific embodiments, the methods
described herein provide a reduction in amorphous content relative to
itioned material of at least 50%. For example, in such embodiments, the
methods described herein provide a reduction in amorphous content ve to
itioned material selected from of at least 75% and at least 90%.
The systems and methods described herein are suited to
conditioning a wide variety of particulate crystalline materials that include, for
example, amorphous material (e.g., particles formed of amorphous material or
crystalline les that include one or more regions of amorphous material)
and/or residual solvent. For example, the systems and methods described
herein are suitable for application to materials exhibiting different al and
chemical characteristics (e.g., water soluble als and materials soluble in
c solvents), and the methods and systems described herein are
applicable to materials prepared for and useful in a wide range of products and
processes, including, for e, industrial chemicals and processes, food
products and additives, cosmetic ts, nutritional products and
formulations, such as ional supplement products, nutraceutical products
and formulations, ceutically active agents, and pharmaceutical
excipients. In the context of food additives and nutritional products, for
example, among many others, the systems and methods described herein may
be utilized to improve the physiochemical stability of one or more of the
following: ame; cyclamate; rin; stevia; sucralose; amino acids;
vitamins; minerals for nutritional supplements; creatine; and ascorbic acid.
Though not limited to such applications, for convenience of
description and exemplification, the disclosure and experimental examples
provided herein describe the present systems and methods in the context of
micronized crystalline materials for use in pharmaceutical products.
Micronization of crystalline active agent and pharmaceutical excipient material
is often employed and can be useful in formulation of pharmaceutical
compositions for a variety of reasons. For example, for a given active agent or
excipient, a crystalline morphology is the most physically and chemically stable
morphology, yet it is often beneficial to reduce the particle size bution of
crystalline materials to facilitate delivery (e.g., micronization to allow respiratory
or pulmonary delivery or to provide improved formulation characteristics,
delivery performance, dissolution performance, and/or bioavailability). Where
micronized material is utilized, however, ving the physiochemical stability
of micronized particulates is also lly important to maintaining the efficacy
and shelf-life of pharmaceutical products incorporating such materials. Though
they are described in the context of ized pharmaceutical materials, the
systems and methods according to the present description can be utilized to
condition a variety of crystalline materials ting any le size distribution
that allows the al to be entrained, suspended, or aerosolized within a
conditioning gas contained within a conditioning zone for a residence time
sufficient to anneal the selected material.
Active agents that can be delivered or formulated as a lline
material can be processed using the systems and methods described herein.
Systems and methods according to the present description are adaptable to
water soluble active agents as well as to active agents soluble in organic
solvents. Examples of active agents that may be sed according to the
present methods include, but are not limited to, beta agonists, inic
antagonists, corticosteroids, PDE4 inhibitors, anti-infectives, diuretics, beta
blockers, statins, anti-inflammatories, including non-steroidal nflammatory
actives, analgesics, and active agents exhibiting a combination of one or more
of the preceding pharmacological effects (e.g., bi- or multifunctional molecules,
such as, for example, a bi-functional muscarinic antagonist and beta agonist).
More specific examples of active agents le for processing
using the systems and methods described herein include steroids, muscarinic
antagonists, R-agonists, and bi-functional compounds ting, for example,
muscarinic antagonist and R-agonists activity suited for respiratory or
pulmonary delivery. Such actives include, for example, short-acting beta
ts, e.g., bitolterol, carbuterol, fenoterol, hexoprenaline, isoprenaline
(isoproterenol), levosalbutamol, orciprenaline (metaproterenol), erol,
procaterol, rimiterol, salbutamol (albuterol), terbutaline, terol, reproterol,
ipratropium and hrine; long-acting P2 rgic receptor agonist, e.g.,
bambuterol, clenbuterol, formoterol, and salmeterol; ultra-long-acting P2
rgic receptor agonists, e.g., carmoterol, milveterol, indacaterol, and
saligenin- or indole-containing and adamantyl-derived P2 agonists;
osteroids, e.g., beclomethasone, budesonide, ciclesonide, flunisolide,
fluticasone, methyl-prednisolone, mometasone, prednisone and trimacinolone;
anti-inflammatories, e.g., fluticasone propionate, beclomethasone dipropionate,
WO 44894
flunisolide, budesonide, tripedane, cortisone, prednisone, prednisilone,
dexamethasone, betamethasone, or triamcinolone acetonide; antitussives, e.g.,
noscapine; bronchodilators, e.g., ephedrine, adrenaline, fenoterol, formoterol,
naline, metaproterenol, salbutamol, albuterol, salmeterol, terbutaline; and
muscarinic antagonists, ing cting muscarinic antagonists, e.g.,
glycopyrronium, dexipirronium, scopolamine, tropicamide, epine,
dimenhydrinate, tiotropium, darotropium, aclidinium, trospium, ipatropium,
atropine, benzatropin, or oxitropium.
Where appropriate, the active agents conditioned using the
systems and methods described herein may be provided as salts (e.g., alkali
metal or amine salts or as acid addition salts), esters, solvates (hydrates),
derivatives, or a free base. Additionally, the active agents may be in any
isomeric form or e of isomeric forms, for example, as pure enantiomers, a
mixture of enantiomers, as racemates or as mixtures thereof. In this regard, the
form of the active agent may be selected to optimize the ty and/or stability.
The systems and methods described herein are also applicable to
excipients, adjuvants, rs, etc. used in pharmaceutical formulations. Such
materials can be processed according to the methods described herein either
individually or in es suitable for formulation. Though not limited to these
specific examples, the systems and methods described herein can be ed to
improve the physiochemical stability of sucrose, a-lactose monohydrate,
mannitol, citric acid, glucose, maltose, arabinose, xylose, ribose, fructose,
mannose, galactose, sorbose, trehalose, sorbitol, xylitiol, maltodextrin, and
isomaltol.
Where a micronized crystalline material is conditioned using the
methods or systems described herein, the material can be prepared to exhibit a
wide range of desired particle size distributions using any suitable micronization
technique. In the t of the present description, the term "micronized"
refers to materials exhibiting a median size as large as, for e, 500
microns, and "micron ization" ses refer to any suitable process by which a
micronized crystalline material is produced. The desired particle size or size
distribution of crystalline material conditioned according to the present
description will depend on, among other s, the nature of the material and
its desired use or application of the material. Techniques suitable for preparing
and providing micronized crystalline material include, for e, milling or
grinding processes, including wet-milling and jet milling processes, precipitation
from supercritical or near-supercritical ts, high pressure homogenization,
spray drying, spray freeze drying, or lyophilization. Examples of patent
references teaching suitable s for obtaining micronized crystalline
particles include, for example, in U.S. Pat. No. 6,063,138, U.S. Pat. No.
,858,410, U.S. Pat. No. 5,851,453, U.S. Pat. No. 5,833,891, U.S. Pat. No.
634, and International Patent Publication No. WO 2007/009164, the
contents of each of which are incorporated herein by reference.
Though the median size of a micronized material may be as large
as 500 pm, often where a micronized material is , the particle size
distribution of the material will be significantly r. For e, in many
contexts requiring micronized material, the material will exhibit a median
particle size of 100 pm or less. In the t of pharmaceutically active agents
or materials prepared for use in pharmaceutical formulations, the median
particle size of the micronized material may be below 50 pm or even 10 pm.
Where the micronized material conditioned according to the methods bed
herein is an excipient or active agent to be used in a pharmaceutical product for
pulmonary delivery, the micronized material is prepared to exhibit a particle size
bution that facilitates pulmonary delivery. In such embodiments, for
e, the micronized material may exhibit a particle size distribution wherein
at least 90% of the active agent particles by volume exhibit an optical diameter
of about 10 pm or less. In other such embodiments, the ized material
may exhibit a particle size distribution wherein at least 90% of the active agent
particles by volume exhibit an optical diameter selected from a range of about
pm to about 1 pm, about 9 pm to about 1 pm, about 8 pm to about 1 pm,
about 7 pm to about 1 pm, about 5 pm to about 2 pm, and about 3 pm to about
2 pm. In still further embodiments where the micronized material is prepared
for use in a pharmaceutical product for pulmonary delivery, the micronized
material may exhibit a particle size distribution wherein at least 90% of the
active agent particles by volume exhibit an l diameter selected from 10
pm or less, 9 pm or less, 8 pm or less, 7 pm or less, 6 pm or less, 5 pm or less,
4 pm or less, 3 pm or less, 2 pm or less, or 1 pm or less.
It will be readily understood that the embodiments, as generally
bed herein, are exemplary. The more detailed description of the systems
and methods provided herein is not intended to limit the scope of the present
disclosure, but is merely entative of various embodiments.
I. Definitions
Unless specifically defined ise, the terms used herein have
their normal meaning as understood in the art. The following terms are
specifically defined for the sake of y.
The term "active agent" as used herein includes any agent, drug,
nd, composition or other substance that may be used on, or
administered to a human or animal for any purpose, including any agent, drug,
compound, composition or other substance that provides a nutritional,
therapeutic, ceutical, pharmacological, diagnostic, cosmetic,
prophylactic agents and/or modulating effect. The term "active agent"
may be used interchangeably with the terms, "drug," "pharmaceutical,"
"medicament," "drug substance," "active pharmaceutical ingredient,"
"pharmaceutically active agent," or "therapeutic." As used herein the "active
agent" may also ass natural or homeopathic ts that are not
generally considered therapeutic.
The term "annealing" refers to a physiochemical change or phase
transformation in a material that results in improved physiochemical stability. In
certain embodiments, the term "annealing" refers to a process whereby
amorphous content within a crystalline particulate material is reduced or
eliminated. In other embodiments, the term "annealing" refers to a process
whereby residual solvent contained within a lline particulate material is
reduced or eliminated by, for example, solvent vaporization and/or ge. In
still further embodiments, the methods and systems described herein may
anneal a crystalline ulate material by both reducing amorphous content
and reducing the presence of a residual solvent.
The term "conditioning," as used herein, lly refers to
methods and processes that may be used to improve the physiochemical
stability of a particulate crystalline material. In ic embodiments, the term
"conditioning" refers to methods that cause a controlled annealing of the
particulate material.
The term "phase transformation" refers to a change in the bulk of
the crystals present in a particulate crystalline al. In particular
embodiments, annealing of a material using the conditioning systems or
methods described herein s in a phase transformation selected from, for
example, removal of a solvent of crystallization, replacement of a solvent of
crystallization, an amorphous to crystalline phase change, or a change in
physical structure beyond just an amorphous to crystalline phase change.
As used herein, "physiochemical" refers to one or both of the
physical and chemical stability of a al.
As used herein, the term it" refers to a reduction, prevention,
or slowing of any given process, event, or teristic.
When used to refer to the ioned particulate material
described herein, the terms "physical stability" and "physically stable" refer to a
composition that is resistant to one or more of particle fusing, aggregation,
agglomeration, and particle size changes. In certain embodiments, physical
ity may be evaluated through exposing the particulate material to
accelerated degradation conditions, such as increased temperature and/or
ty as described herein.
When referred to herein, the term "optical diameter" indicates the
size of a particle as measured using a laser diffraction particle size analyzer
equipped with a dry powder dispenser (e.g., Sympatec GmbH, hal
Zellerfeld, Germany).
WO 44894
11. Systems for Conditioninq Particulate Crystalline Material
Figure 1 es a schematic illustration of an embodiment of a
system for ioning particulate crystalline material according to the present
description. The system 100 includes a delivery zone 110, wherein one or
more crystalline materials (e.g., one or more pharmaceutically active agents or
pharmaceutically acceptable excipients or adjuvants) may be red and
prepared for mixing with a conditioning gas. The system also includes a
conditioning gas supply zone 120. The conditioning gas is ed from the
conditioning gas supply zone 120, and in certain embodiments, the conditioning
gas is generated within the conditioning gas supply zone 120. The crystalline
particulate material and the conditioning gas may be introduced into a mixing
zone 130, after which they enter a conditioning zone 140. The conditioning
zone 140 includes a controlled atmosphere contained and maintained within a
conditioning chamber. The controlled atmosphere includes the conditioning
gas and any delivery gas used for ring the crystalline particulate al,
and the particulate material being conditioned s entrained, suspended,
or lized within the controlled atmosphere within the ioning
chamber. The crystalline material undergoes an annealing process within the
conditioning zone 140 as it is maintained within the conditioning zone 140 for a
d residence time. The micronized material may be separated from the
conditioning gas and collected from the conditioning zone 140 in the separation
and collection zone 150, which can include any of a number of well-known
components suited to the collection of micronized material.
The nature of and extent to which annealing of the particulate
material takes place can be controlled by the nce time of the material
within the conditioning zone and by the properties of the conditioning gas,
including, for example the presence and concentration of one or more solvents,
and the temperature, flow rate, and direction or turbulence of flow of the
conditioning gas. In some embodiments of the systems disclosed herein, the
residence time of the micronized active agent particles in the conditioning zone
2014/029489
140 may be controlled by the geometry of the conditioning zone 140 or by the
flow rate of the conditioning gas through the conditioning zone 140.
The material to be conditioned may be ed to the delivery
zone 110 in a form that is appropriate for the chosen material and the
ioning s. Where a particulate material exhibiting a desired particle
size distribution is desired, the material may be prepared to exhibit the targeted
particle size distribution prior to introduction into the delivery zone 110. In such
an embodiment, the particulate material can be fed from the delivery zone 110
into the mixing zone 130 using any le device or system for controlled
feeding of a powder or particulate material at a desired feed rate. Controlled
feeding of the particulate material will typically include entraining the particulate
material in a dispersion component, such as, for example a delivery gas
suitable for dispersion and delivery of the particulate material into the mixing
zone 130 and/or the conditioning zone 140.
In certain embodiments, particulate al may be subjected to
a micronization process within the delivery zone 110. In such embodiments,
the delivery zone 110 may e a device or system that processes the
crystalline material to provide a micronized particulate material that exhibits a
desired particle size distribution. Where the delivery zone 110 includes a
device or system suitable for carrying out micronization of the selected
crystalline material, the ry zone 110 may incorporate any one of a number
of known devices or systems for micronization. For e, the crystalline
material may be micronized in the delivery zone 110 using known milling or
grinding processes, known crystallization or recrystallization processes, or
known ization ses utilizing precipitation from supercritical or near
ritical ts, spray drying, spray freeze drying, or lyophilization.
In embodiments where the delivery zone 110 includes a
micronizer, the mixing zone 130 and/or conditioning zone 140 may be operably
linked to the micronizer. In such embodiments, the crystalline material may be
processed to exhibit the targeted particle size distribution within the delivery
zone 110 and, prior to collection, immediately delivered to the mixing zone 130
while the particles remain airborne as they exit from the micronizer. Therefore,
the s and methods described herein allow for conditioning of micronized
material as a sequential but integrated step in a process of producing and
collecting a micronized crystalline material. Such "in-line" or "in-process"
conditioning of micronized crystalline material provides the benefits ated
with the annealing achieved by the ioning process, while also eliminating
the need to conduct a first process for producing micronized (or size
comminuted) material followed by a second, separate conditioning process for
annealing the micronized al.
The mixing zone 130 illustrated in Figure 1 is shown as separate
from the conditioning zone 140. In such an embodiment, the lline
material to be conditioned (such as, e.g., micronized material suspended or
ned within a delivery gas) and the conditioning gas are delivered to the
mixing zone 130 prior to their entry into the conditioning zone 140. The mixing
zone 130 can be sized and configured as desired to achieve desired mixing of
the particulate material and conditioning gas. In certain embodiments, the
mixing zone 130 may include a sion head assembly into which both the
particulate material and the conditioning gas are fed and directed into the
conditioning zone 140. Alternatively, in other embodiments, the mixing zone
130 may be an area within the conditioning zone 140 where the particulate
material and the conditioning gas are delivered into the conditioning zone in a
manner that lishes the mixing ed for annealing of the particulate
material within the conditioning zone. In such embodiments, the micronized
material may be introduced into the ioning zone as a particulate material
entrained or aerosolized within a delivery gas, and the conditioning gas may be
introduced into the conditioning chamber such that the conditioning gas begins
to mix with the ry gas and the micronized material disbursed therein upon
entry into the ioning zone 140.
The conditioning zone 140 may be formed within a conditioning
chamber, which can be provided by any structure, such as a column, tank,
tube, funnel, coil, or the like, suitable for maintaining a controlled atmosphere
and receiving the particulate material and conditioning gas. The characteristics
of the controlled atmosphere within the conditioning zone 140 can be adjusted
to achieve a desired ioning of one or more selected particulate materials.
In particular embodiments, the conditioning gas is red at a specified rate
and mixes with the delivery gas at a ed ratio. For example, the
conditioning gas may be supplied to the conditioning zone 140 (e.g., through a
dispersion head assembly) at a targeted gas flow rate. The gas flow rate will
depend on, among other factors, the amount of micronized material being
processed and the angle at which the gas is introduced into the conditioning
zone 140. In certain embodiments, the conditioning gas is introduced into the
conditioning zone 140 at a rate g from about 20 SCFM up to about 500
SCFM, and the delivery gas having the particulate material to be conditioned
entrained therein may be supplied at a gas flow rate ranging from about 20
SCFM up to about 75 SCFM. However, depending on the angle at which the
conditioning and ry gases are introduced into the conditioning zone 140
and the nature of the material being processed, the gas flow rate of both the
ioning gas and the delivery gas may be increased as high as 3,300
SCFM. In other embodiments, the conditioning gas may be supplied at a flow
rate of 30 SCFM up to about 100 SCFM and the delivery gas containing the
micronized material to be conditioned may be ed at a gas flow rate
ranging from about 30 SCFM up to about 60 SCFM. In addition to, or as an
alternative to, controlling the rate at which the conditioning gas is introduced
into the lled atmosphere, the ratio of the conditioning gas to the delivery
gas may be selected to facilitate conditioning of the micronized material. In
particular embodiments, the conditioning gas is mixed with the delivery gas at a
ratio selected from 1:1, 1.2:1, 1.4:1, 1.6:1, 1.8:1, 2.0:1, 2.2:1, 2.4:1, 2.6:1, 2.8:1,
3:1, 3.2:1, 3.4:1, 3.6:1, 3.8:1, and 4:1.
The ature of the conditioning gas may also be controlled.
Annealing of particulate material can be icantly affected by temperature.
In certain embodiments, the temperature of the conditioning gas is selected
from between about 100 C and 1000 C. In specific examples of such
embodiments, the temperature of the conditioning gas may be selected from
one of the following ranges, between about 100 C and 700 C, between about
200 C and 500 C, between about 100 C and 500 C, and between about 200 C
and 300 C, depending on the nature of the particulate material being processed.
The conditioning gas may also include one or more solvent
vapors. In such embodiments, the conditioning gas includes a carrier gas
having one or more solvent vapors dispersed therein. The inclusion of a
solvent vapor within the conditioning gas can be particularly useful in
conditioning processes adapted to reduce or eliminate amorphous content and
to conditioning process d to reduce or eliminate the presence of residual
solvent(s) by t ge.
Where a solvent is included in the conditioning gas, the solvent
will typically be selected according to the material to be conditioned. For
example, in embodiments where the material to be conditioned is water soluble,
the conditioning gas may include water vapor carried within an inert gas. In
certain embodiments, the solvent vapor may be a combination of water and
water miscible organic solvents (e.g., alcohols, ketones, esters, etc.)
Alternatively, in embodiments where the material to be conditioned is not water
e, but exhibits solubility in one or more organic solvents, the t vapor
ed in the conditioning gas may simply include an organic solvent vapor,
such as an alcohol (e.g., l, methanol, isopropyl alcohol, etc.), ketone
(e.g., acetone, methyl ketone, ethyl ketone, etc.), ester (e.g., ethyl e,
etc.), tic alcohol (e.g., octanol, etc.), or alkane (e.g., octane, nonane, etc.)
vapor, carried within an inert gas. As used herein, "inert" refers to a carrier gas
that is non-reactive with the micronized material being conditioned and
preferably the t vapor. Examples of inert gases include, t
limitation, compressed dry air, nitrogen, inert gas (e.g., argon, helium, etc.),
carbon dioxide, and the carrier gas included in the conditioning gas can be
selected ing to the solvent vapor or combination of solvent vapors to be
used in the conditioning gas or conditioning zone. In embodiments where the
conditioning of the particulate al includes solvent exchange, the
WO 44894
solvent(s) included in the conditioning gas may be selected to provide improved
safety and/or physiochemical stability of the particulate material.
Where a solvent is ed in the conditioning gas, the
conditioning gas can be prepared and maintained at a specified temperature or
temperature range in order to maintain the solvent as a vapor. As already
mentioned, controlling the temperature of the conditioning gas can also serve to
facilitate the conditioning process, with the temperature being selected to
facilitate a desired level of annealing over a selected residence time.
The relative concentration of solvent vapor included in a
conditioning gas can also be ed to accomplish a desired level of
conditioning for different material characteristics. For example, the
concentration of solvent vapor within the conditioning gas may be adjusted
based on the chemical or physical properties of the crystalline material to be
processed. In ic embodiments, the relative humidity (RH) or relative
saturation (RS) and temperature conditions of the conditioning gas are selected
to provide RH or RS and temperature conditions that exceed the glass
transition temperature (Tg) of the ous content of the material being
processed. For example, for each of the solvents included within the
conditioning gas, the vapor pressure of the solvent may be maintained at a
vapor pressure of about 0.05 to 0.95 of the saturation vapor pressure for the
solvent.
Crystallization of an amorphous phase typically occurs rapidly
when the amorphous material is exposed to conditions that exceed its glass
transition temperature, usually twenty degrees Celsius above the glass
transition temperature (Lechuga-Ballesteros, D.; Miller, D. P.; Zhang, J.,
Residual water in ous solids, measurement and effects on stability. In
Progress in Amorphous Food and ceutical Systems, , H., Ed.
The Royal Society of Chemistry: London, 2002; pp 275-316). re of
amorphous material to temperature in excess of the glass transition can be
ed in the absence of any solvent by exposing the amorphous al to
a stream of hot air above its glass tion temperature. However, the glass
tion temperature is also a on of the on of t present in the
amorphous material, an effect known as cization. Plasticization is typically
ented by a plasticization curve, such as the one shown in Figure 16,
which shows the Tg of a given amorphous material as a on of solvent (in
this case water) content.
In addition, the solvent content held in an amorphous material is a
function of the vapor concentration of the solvent surrounding the amorphous
solid. This can be illustrated by the sorption isotherm provided in Figure 17.
The sorption isotherm of a given material is a representation of the amount of
solvent in the amorphous material as a function of the solvent activity (which is
proportional to the solvent vapor pressure to saturation solvent vapor pressure
ratio) at a given temperature.
The glass transition plasticization curve and the sorption isotherm
can be ed to construct a stability diagram as the one shown in Figure 18
for the selected al. The stability diagram shown in Figure 18 is one
created for glycopyrrolate. The stability diagram can be used to choose
operational conditions for the systems and methods bed herein that
promote fast annealing of the crystalline material selected for conditioning. For
example, as is illustrated in Figure 18, in the case of glycopyrrolate fast
llization of amorphous material will occur at RH>50% in the range of 20
400C, and at 600C it would only require 10%RH to promote annealing.
The nature and extent of annealing that takes place within the
conditioning zone can also be adjusted by altering the residence time of the
particulate material within the conditioning zone 140. The residence time is the
average time particulate material spends within the conditioning zone 140. The
residence time of the particulate material within the conditioning zone 140 can
be adjusted by changes to one or more of a variety of process variables. For
example, the volume and dimensions of the conditioning chamber can be
altered, to provide longer or shorter residence times, with, for example,
vely higher volume or larger physical dimensions generally resulting in
relatively longer residence times. The flow rates and temperatures of one or
both of the conditioning gas and the ry gas can also be adjusted to affect
residence time. In addition, the manner by which the conditioning gas or
delivery gas is introduced into the conditioning chamber can affect le
residence time. As an example, introduction of the conditioning gas and/or
delivery gas in a manner that creates a generally linear flow through the
conditioning chamber may create a relatively shorter residence time compared
to introduction of the same gas(es) in a manner that s a more turbulent
recirculating sion of the gas(es).
In general, the residence time of the particulate material within the
conditioning chamber can be selected from about 0.5 seconds to several
minutes. In particular embodiments, the residence time may be up to about 10
minutes or 600 seconds. In particular embodiments, the residence time may be
selected from about 0.5 to about 10 seconds, 0.5 to about 20 seconds, 0.5 to
about 30 seconds, 0.5 to about 40 seconds, and 0.5 to about 50 s. In
certain such embodiments, the particulate al may be conditioned by the
conditioning gas for a residence time selected from about 0.5 seconds, 1
second, 1.5 seconds, 2 seconds, 2.5 seconds, 3 seconds, 3.5 seconds, 4
seconds, 5 seconds, 6 seconds, 7 seconds, 8 s, 9 seconds, and 10
seconds.
After the particulate material has been annealed in the
ioning zone 140, the conditioned al is separated from the
conditioning gas and collected in the separation and collection zone 150. The
ized material may be separated and collected from the conditioning gas
using known particle collection techniques and equipment. In certain
embodiments of the systems disclosed herein, the micronized material may
continue to anneal while in the separation and collection zone 150. The
collection zone 150 can be formed by or include a cyclone collector. Cyclone
collectors for collection of particulate als, including micronized materials,
and separation of such materials from a conditioning gas. e collectors
are commercially available and suitable for use as the collection zone 150 of
the systems described herein.
2014/029489
In addition to a collection device, such as a cyclone tor, the
collection zone 150 may be configured to facilitate direct collection of the
processed al. Where a collection zone 150 is configured to allow direct
collection of the conditioned material, the collector included in the collection
zone may simply deliver the conditioned product to a container from which the
conditioned material can be collected or removed. Such a container may
include a tion bag that can be removed from the collection device, as is
often used in conjunction with a cyclone collector. The collection bag may be
sealable and formed using a material that enables efficient collection of the
conditioned material, while also being permeable to a gas used in the collection
system. In another embodiment, the collector ed in the tion zone
150 may be configured as a holding chamber. In such an embodiment, the
collector, such as a cyclone collector, may be used to separate the conditioned
material from a conditioning gas and collect the conditioned material into a
holding chamber where the ioned material can be maintained in a
fluidized state for a desired period of time. Annealing of the crystalline material
processed according to the present description is not always complete as the
material exits the conditioning zone 140, and may continue as the material is
collected. ing on the material being processed and the annealing
conditions, it may be beneficial to maintain the conditioned material in a
fluidized state within a collection chamber for a period of time sufficient to allow
additional progress of the annealing process.
In still other embodiments, the collection zone 150 may be
ured to allow further sing of the conditioned material. In such
embodiments, the collection zone 150 may be operably linked to one or more
additional systems, including an additional conditioning system as described
herein, for further sing of the conditioned material. In such
embodiments, the tor ed in the collection zone 150 may be
configured to deliver the conditioned material directly for continued processing
or the collection zone 150 may be configured to e or be in operable
communication with a holding chamber as described and illustrated herein,
WO 44894
such as, for e, in association with the systems illustrated in Figure 19
and Figure 20.
In some embodiments, the systems and methods described
herein may be utilized to simultaneously process and condition more than one
particulate material. For e, two or more micronized materials may be
simultaneously introduced into a conditioning zone. The materials may be
combined prior to introduction into the conditioning zone or they may be
introduced independently into the conditioning zone. In some embodiments,
the materials may be combined prior to micronization and introduced into the
ioning zone as a particulate material including a combination of two or
more chemical es. Even further, where two or more different particulate
materials are introduced into the conditioning zone (whether as a combined
product stream or as two or more independently introduced materials), the
materials may exhibit similar lity characteristics (e.g., each of the different
materials t solubility in water or each of the materials exhibit solubility in a
given c solvent). However, the methods described herein are also suited
to simultaneously conditioning two or more materials in the same conditioning
zone where at least two of the two or more different materials t different
solubility characteristics (e.g., at least one is water soluble, while another is
soluble only in an organic solvent, or one is soluble in a first organic solvent,
while a second is soluble in a second organic solvent).
Certain embodiments of a system for the in-process conditioning
of a micronized material according to the present description can be
represented by the system illustrated in Figure 2. Because the delivery zone of
the system illustrated in Figure 2 includes a device configured for the
micronization of the al to be ioned, the ry zone of the system
will be referred to as a micronizing zone 210. As shown in Figure 2, the
micronizing zone 210 may be configured to deliver aerosolized micronized
particles directly into a mixing zone 230. In specific embodiments, the
micronization zone 210 includes a jet mill 213 and the crystalline material 211
to be micronized is delivered to the jet mill 213 using a standard feeder 212.
After micronization, the micronized material 235 may be delivered through an
outlet 214 as aerosolized particles d by a delivery gas 216 and supplied to
the mixing zone 230.
The micronized crystalline material is ed to the mixing zone
230 as a micronized material with a d le size distribution. In certain
embodiments, for example, at least 90% of the micronized particles by volume
exhibit an optical diameter of about 10 pm or less. In other embodiments, at
least 90% of the micronized crystalline particles by volume exhibit an optical
diameter selected from a range of about 10 pm to about 1 pm, about 9 pm to
about 1 pm, about 8 pm to about 1 pm, about 7 pm to about 1 pm, about 5 pm
to about 2 pm, and about 3 pm to about 2 pm. In further embodiments, at least
90% of the micronized crystalline particles by volume t an optical
diameter selected from 10 pm or less, 9 pm or less, 8 pm or less, 7 pm or less,
6 pm or less, 5 pm or less, 4 pm or less, 3 pm or less, 2 pm or less, or 1 pm or
less.
The micronizing zone 210 may be separated from an external
environment or contained within a safety barrier or ure (not shown).
Such a design can be particularly advantageous where the micronized material
is an active agent or is otherwise biologically active. The safety barrier may be
used in order to prevent unwanted contact with any ized material
produced in the micronizing zone 210. Where included in the systems
described herein, a safety r may be constructed of any suitable material
such as metal, glass, plastic, composites, etc., that are sufficient to contain
micronized particles.
With nce to Figure 2, in particular embodiments, the
conditioning gas 226 utilized in an in-line conditioning system may be prepared
within the conditioning gas supply zone 220. For example, the conditioning gas
supply zone 220 may include a heating chamber 221 to which a carrier gas 222
may be provided for heating to a desired temperature. In one such
embodiment, the g chamber 221 comprises a heat source, such as an
ic heater or furnace, for heating the carrier gas 222. The carrier gas 222
provided for use in the systems disclosed herein may comprise one or more
gases suitable for the methods described herein for conditioning a given
micronized crystalline material. For example, the carrier gas 222 may comprise
one or more inert gasses or atmospheric gasses such as those described
herein, ing, for example, compressed air, nitrogen, oxygen, and helium.
The conditioning gas supply zone 220 may further comprise a
liquid evaporation chamber 225. The t used to produce the solvent vapor
disbursed within the r gas 222 can be ted within or provided from
the evaporation chamber 225, and the evaporation chamber can be configured
to provide the carrier gas 222 with a desired concentration of solvent vapor
within the conditioning gas 226. Where the micronized crystalline material is
water soluble, the solvent can be an aqueous solvent, such as purified or
distilled water, and in such embodiments, the evaporation chamber 225 is
configured to create a conditioning gas 226 having a d relative humidity.
In other embodiments, particularly where the micronized crystalline material to
be conditioned is not water soluble, the solvent for use with the s
disclosed herein may be a non-aqueous liquid, such as an organic solvent
described herein.
A liquid atomizer 223 may be used to deliver liquid solvent to the
carrier gas 222 in the form of atomized liquid droplets 224 suspended within the
carrier gas 222. Atomization of the liquid solvent facilitates conversion of the
liquid solvent into a solvent vapor within the evaporation chamber 225. In more
specific embodiments, a liquid er used in the systems described herein
provides control over the size of the atomized droplets delivered to the carrier
gas 222 as well as the rate and volume of liquid solvent atomized. Where
used, a liquid er 223 can be selected from, for example, pressure
nozzles, tic atomizers, impinging jet atomizers. In one such
embodiment, the r gas 222 is heated in the heating chamber 221, a liquid
atomizer 223 delivers liquid t to the carrier gas within the conditioning
gas supply zone 220, and the carrier gas 222 and atomized liquid solvent 224
are ed to the liquid evaporation chamber 225. As the carrier gas 222 and
WO 44894 2014/029489
atomized liquid t 224 pass through the liquid evaporation r, the
liquid solvent vaporizes and the carrier gas becomes a conditioning gas 226
having a desired solvent vapor concentration.
In certain embodiments, where the solvent vapor is formed from
an aqueous solvent, the conditioning gas 226 may be supplied at a temperature
ranging from about 20 0C to about 100 0C, and with a relative humidity ranging
from about 0.05% to about 75%. In more specific embodiments where the
solvent used to form the solvent vapor is an aqueous solvent, the conditioning
gas 226 may be supplied having a temperature selected from at least about 20
C, 21 C, 22 C, 23 C, 24 C, 25 C, 26 C, 27 C, 28 C, 29 C, and 30 0C
and having a relative humidity selected from at least about 50%, 51%, 52%,
53%, 54%, 55%, 56%, 57%, 58%, 59%, 60%, 61%, 62%, 63%, 64%, 65%,
66%, 67%, 68%, 69%, 70%, 71%, 72%, 73%, 74% and 75%. In particular
ments, r, the temperature may be as high as 22 0C and the
relative humidity as low as 0.05%.
With continued reference to Figure 2, the mixing zone 230 is
configured to mix incoming micronized crystalline material 235 with the
conditioning gas 226. In particular ments, the mixing zone 230 is
configured to mix a delivery gas flow 216 with a conditioning gas 226. In some
embodiments of the s disclosed herein for in-process conditioning of
micronized active agents, the mixing zone 230 may comprise a dispersion head
assembly configured to mix the delivery gas 216 with the conditioning gas 226.
With reference to Figures 3A, 3B, and 3C, a dispersion head ly 330
suitable for use in the systems described herein may include a g 335 and
a mixing head 340, wherein a conditioning gas 326 and a delivery gas 316 may
be mixed. The housing 335 comprises a conditioning gas inlet 324 and a gas
outlet 325, wherein the conditioning gas 326 may be supplied to the dispersion
head assembly 330 through the conditioning gas inlet 324. As shown in Figure
3C, the conditioning gas 326 may be delivered to the mixing head 340 where it
can enter an injection nozzle 345 through an injection inlet 342. The mixing
head 340 may also comprise a delivery gas inlet 350 through which the delivery
gas 316, having the micronized material entrained therein, may enter the
injection nozzle 345. As the delivery gas 316 and the conditioning gas 326
enter the injection nozzle 345 they are mixed together thereby ng the
micronized crystalline material to the conditioning gas 326.
Where a mixing head is ed in a system according to the
present description, as shown in Figure 3, the mixing head may be able
and hangeable such that the mixing head 340 may be removed from the
dispersion head assembly 330 and modified or exchanged for a different mixing
head. The design of the mixing head 340, such as the size, shape, number,
and location of one or more injection nozzle inlets 342, may be modified and
ed to control the mixing dynamics, volume, and/or rate at which the
delivery gas and conditioning gas exit the mixing head 340 and are delivered to
the conditioning zone 240. In specific embodiments, the design of the mixing
head 340, including the size, shape, and location of the delivery gas inlet 350,
may be ed and adjusted to control the mixing cs and the volume
and/or rate of mixed gases that exit the mixing head 340.
In certain embodiments, the dispersion head assembly and/or
mixing head may be configured to mix the conditioning gas and the micronized
crystalline material upon entry into the conditioning zone 240. Alternatively, the
dispersion head assembly and/or mixing head may be configured to mix the
conditioning gas and micronized crystalline material before the e leaves
the mixing zone 230 and is delivered to the conditioning zone 240. For
example, Figures 4A and 4B provide further embodiments of ent mixing
heads that may be used in the systems described herein. Figure 4A shows
mixing head 420 comprising delivery gas inlet 450 and injection nozzle inlet 425
located near the base of the injection nozzle 445. Figure 4B shows a mixing
head 430 comprising a delivery gas inlet 450 and ion nozzle inlet 435
located near the edge of the injection nozzle 445. In further embodiments, the
mixing heads disclosed herein may include one or more injection nozzle inlets
located at desired positions within or around the injection nozzle 445. In other
embodiments, the conditioning gas and the micronized crystalline material may
WO 44894
be mixed in the injection nozzle 445 before the mixture leaves the mixing zone
230 and is delivered to the conditioning zone 240.
The systems disclosed herein can include a mixing zone 230
configured to mix the conditioning gas 226 with the delivery gas 216 in a
desired ratio, such as a ratio of gas volumes (volume/volume) or a mass flow
rate ratio (SCFM/SCFM). For example, in particular ments, the mixing
zone, including, for example, a dispersion head assembly, may be configured to
mix the conditioning gas 226 and delivery gas 216 in a ratio of about 1 to 4
parts conditioning gas 226 with about 1 part of the delivery gas 216. In certain
such embodiments, the conditioning gas 226 may be mixed with the ry
gas 216 in a ratio selected from any of about 1:1, 1.2:1, 1.4:1, 1.6:1, 1.8:1,
2.0:1, 2.2:1, 2.4:1, 2.6:1, 2.8:1, 3:1, 3.2:1, 3.4:1, 3.6:1, 3.8:1, and 4:1.
With ued reference to Figure 2, the conditioning zone 240
(also referred to herein as a "conditioning chamber") included in the systems
described herein is configured to contain and maintain a controlled atmosphere
tailored to the conditioning of a desired ized material and to receive the
delivery gas 216 and conditioning gas 226 from the mixing zone 230. As noted
above, in some embodiments, the conditioning chamber 240 and mixing zone
230 may be provided as separate subsystems placed in fluid communication
one with r. atively, the mixing zone 230 and ioning chamber
240 may be integrated such that two different subsystems are not required.
Where, provided as separate subsystems, the mixing zone 230 and
conditioning chamber 240 are configured such that the mixed delivery gas 216
and conditioning gas 226 are delivered into the conditioning chamber 240 from
the mixing zone 230.
In certain ments, after the conditioning gas 226 and the
delivery gas 216, comprising micronized active agent particles, are mixed
together in the mixing zone 230, the micronized les 235 enter the
conditioning chamber 240 together with the conditioning gas 226. While in the
conditioning chamber 240, the micronized particles 235 are exposed for a
desired time period to the conditioning gas 226, and during their residence time
2014/029489
within the ioning chamber 240, the amorphous material included in the
micronized particles 235 anneals. The residence time of the micronized
particles 235 in the conditioning chamber 240 may be controlled by one or more
of the following: the dimension and geometry of the conditioning r 240;
the rate at which the mixture of the conditioning gas 226 and the delivery gas
216 are delivered into the conditioning chamber 240; the flow pattern of the
mixture of the conditioning gas 226 and the delivery gas 216 within the
conditioning chamber 240; the amount of micronized material carried by the
e of delivery gas 216 and conditioning gas 226; and the system used for
collection of the conditioned micronized material. In particular embodiments,
the residence time of the micronized active agent particles 235 within the
conditioning chamber 240 may be for a period of time ranging from about 0.5 to
seconds. In certain such embodiments, the nce time of the
ized particles 235 within the conditioning chamber 240 may be selected
from one the nce times detailed herein.
A conditioning chamber 240 suitable for use in the systems
described may be configured as for e, a tank, a column, a funnel, a tube,
or other appropriate s or structures. In further ments, the
conditioning chamber 240 may further include heaters, inlets, outlets, and other
means and devices for controlling the conditions and gas flow within the
conditioning chamber 240. The geometry of the ioning chamber 240 may
be modified by adjusting, for example, the length, width, height, volume, and
shape of the conditioning chamber 240.
Conditioned micronized active agent particles 246 are separated
from the ioning gas 226 in a separating zone 250. The separating zone
250 may comprise elements or devices designed to separate ioned
micronized active agent particles 246 from the carrier gas 216 and conditioning
gas 226, such as, for example, a cyclone separator, bag collector or other
separation equipment, as known by those of skill in the art. In particular
embodiments, the separating zone 250 may comprise an exhaust outlet 255
whereby, for example, the exhaust gas and other materials may exit from the
separating zone 250. Though micronized material will have been conditioned
within the conditioning zone 240, in certain embodiments, the process of
annealing is does not end immediately upon collection of the micronized
material from the ioning zone 240. For example, in n embodiments,
although the controlled atmosphere of the conditioning zone 240 initiates or
even substantially tes the annealing process, annealing of amorphous
material continues as the ized material exits the conditioning zone 240
and is separated and collected. In addition to a system or device of separating
the conditioned micronized material from the delivery and conditioning gases,
the separating zone 250 may further included one or more filters and collectors.
Filters may be placed, for example, at the exhaust outlet 255 to e or
prevent unwanted escape of fines. Additionally, a collector 260 is included
within the separating zone 250 to facilitate capture and containment of the
conditioned material. Once collected the, conditioned crystalline material can
be stored or further processed, as d.
Though Figure 1 and Figure 2 illustrate conditioning systems
having a single conditioning zone, s according to the present description
may also e multiple conditioning zones. In such embodiments, the
different conditioning zones may expose the crystalline particulate al to
different annealing conditions. Such s, therefore, can be configured to
provide multiple in-process conditioning steps. Figure 19 and Figure 20 provide
schematic illustrations of two embodiments of conditioning systems that e
two conditioning zones, thereby facilitating multiple annealing steps within a
single system.
As shown in Figure 19, a conditioning system 600 as described
herein may include a ry zone 610, a conditioning gas supply zone 620, a
mixing zone 630, a conditioning zone 640, and a collection zone 650, as
described herein. In addition, the system may include a product holding
chamber 660 that is separated from the collection zone 650 by, for example, a
cut-off valve 670. In such an embodiment, the ioning system can be
configured as described in relation to the systems illustrated in Figure 1 and
Figure 2, and the system can be adapted for annealing a wide range of
materials using any suitable process conditions described herein. As
conditioned product is collected in the collection zone 650, the cut-off valve 670
remains open and conditioned t is delivered to the product holding
chamber 660. The product holding chamber 660 can be configured to maintain
the conditioning product in a uously fluidized state. The cut-off valve 670
can be any valve mechanism suited to use in this context, that can be cycled
between open and closed states, and when closed provides a physical barrier
capable of separating the ioned material from collection zone 650. In
certain embodiments, the cut-off valve 670 seals the product holding r
660 from the collection zone 650 such that, once closed, the conditioned
product will not regress into the collection zone 650 and process gases (e.g.,
delivery gas or conditioning gas) do not pass between the collection zone 650
and the product holding chamber 660.
Once delivered to the product g chamber 660, the
conditioned product may be maintained in a fluidized state and the cut-off valve
670 closed. At that point, the system can re-equilibrate to supply a ary
conditioning gas. In such an embodiment, the upstream components of the
conditioning system 600 (e.g., the delivery zone 610, ioning gas supply
zone 620, mixing zone 630, conditioning zone 640, and collection zone 650)
may be purged of the primary conditioning gas used to condition the material
present in the product g r 660, and a secondary conditioning gas
can be supplied from and/or generated in the gas supply zone 620. Once the
system is re-equilibrated with the secondary conditioning gas, the cut-off valve
670 may be opened to expose the conditioned product contained within the
product holding chamber 660 to the secondary ioning gas. The product
can be maintained in a continuously fluidized state within the product holding
r 660 as it is exposed to the secondary conditioning gas for a period of
time sufficient to accomplish a secondary annealing. The nature and content of
the secondary conditioning gas, including the ce and concentration of
one or more solvents, and the temperature, flow rate, and direction or
turbulence of flow of the secondary ioning gas may be adjusted to
accomplish a desired secondary annealing for a wide range of selected
materials using process conditions bed . By adjusting the
characteristics of the ary conditioning gas and the residence time of the
particulate material within the product holding chamber 660, the system
illustrated in Figure 19 can be utilized to provide multiple conditioning steps
using a single system.
The residence time of the conditioned t within the holding
chamber 660 can be easily adjusted based on the al itself, the
conditioning gas(es), and the nature or extent of annealing desired. For
example, as is true of particles conditioned within a conditioning zone, the
residence time of a conditioned product within a holding chamber 660 may be a
matter of seconds or minutes. For example the residence time of the
conditioned material within the holding chamber 660 may be selected from
those residence times detailed above in relation to the conditioning zone.
However, the conditioned product can also be maintained within the holding
chamber 660 indefinitely. In certain embodiments, the conditioned product is
maintained within a holding chamber 660 for a time selected from up to 5
minutes, up to 10 minutes, up to 30 minutes, up to 1 hour, up to 1.5 hours, up to
2 hours, up to 5 hours, up to 10 hours, up to 12 hours, up to 18 hours, and up to
24 hours. Such ility enables the conditioned product to be exposed to a
secondary conditioning gas for any amount of time needed to accomplish
secondary conditioning. A relatively longer residence time affords exposure to
a secondary conditioning gas over a long period of time and may be particularly
useful for a secondary conditioning process that requires more time than might
be practically achieved within a given system's conditioning zone.
Figure 20 illustrates a conditioning system 700 that es two
ioning tems, a primary conditioning system 701 and secondary
conditioning system 801. The primary conditioning system 701, includes a
ry zone 710, a primary conditioning gas supply zone 720, a primary
mixing zone 730, a primary conditioning zone 740, and a y collection
zone 750. The primary conditioning system 701 and the secondary
conditioning system 801 may be separated by, for example, a y holding
chamber 760 and one or more cut-off valve 770 (only a single cut-off valve is
shown). The primary holding chamber 760 may be configured for maintaining
ioned product received from the primary conditioning system 701 in a
continuously fluidized state, and the cut-off valve 770 can be any valve
mechanism suited to use in this context, that can be cycled between open and
closed states, and when closed es a physical barrier capable of isolating
the y and secondary conditioning systems 701, 801. In n
embodiments, the cut-off valve 770 seals the primary holding chamber 760
from the secondary conditioning system 801 such that, when closed, product
collected from the primary conditioning system 701 will not pass into the
secondary conditioning system 801, material transferred to the secondary
conditioning system 801 will not regress into the primary conditioning system
701, and process gases (e.g., ry gas or conditioning gas) do not pass
between the primary and secondary conditioning systems 701, 801. In some
embodiments, a second cut-off valve (not shown) can be positioned between
the primary holding r 760 and the primary collection zone 750. Such a
configuration may be particularly advantageous where communication of
process gases between the primary and secondary conditioning systems 701,
801 must be minimized.
As shown in Figure 20, the secondary conditioning system 801
may include a secondary conditioning gas supply zone 820, a secondary mixing
zone 830, a secondary conditioning zone 840, and a secondary collection zone
850. In the embodiment illustrated in Figure 20, the primary and secondary
conditioning systems 701, 801 can be configured as described in relation to the
systems illustrated in Figure 1 and Figure 2, and the systems can be adapted
for conditioning a wide range of materials using any process conditions
described .
As al is processed in the y conditioning system 701 a
primary annealing of the material takes place and the primary annealed
material is collected in the primary collection zone 750 and red to the
primary holding chamber 760. While the product is processed in the primary
conditioning system 701 and collected in the y holding chamber 760, the
cut-off valve 770 will typically remain closed. Once the first conditioning
process is complete and the primary annealed al is collected in the
primary holding r 760, the cut-off valve 770 may be opened and the
primary ed material delivered into the secondary mixing zone 830. The
primary annealed material may be dispersed within a delivery gas as it is
delivered to or within the secondary mixing zone 830. The delivery gas can be
any suitable delivery gas as described herein, and by dispersing the primary
annealed product in a delivery gas, the primary annealed product is suspended
or entrained within the delivery gas. A secondary ioning gas is delivered
and/or generated within the secondary conditioning gas supply zone 820, and
the secondary conditioning gas is mixed with the primary annealed product
(and any delivery gas used to se the primary annealed product) in the
secondary mixing zone 830.
The primary annealed product remains entrained, suspended or
aerosolized in the secondary conditioning gas within the secondary ioning
zone 840. The primary ed product is maintained within the secondary
conditioning zone 840 for a period of time sufficient to accomplish a secondary
annealing. As is true of the conditioning gas utilized in each embodiment of the
systems bed herein, the nature and content of the secondary conditioning
gas, ing the ce and concentration of one or more ts, and the
temperature, flow rate, and direction or turbulence of flow of the secondary
conditioning gas may be adjusted to accomplish a desired secondary ing
for a wide range of selected materials using process conditions described
herein. By adjusting the characteristics of the secondary conditioning gas and
the residence time of the particulate material within the secondary conditioning
zone 840, the system illustrated in Figure 20 can be utilized to provide multiple
conditioning steps using a single system.
Though bed in relation to embodiments illustrated in the
figures provided herein, conditioning systems according to the present
ption are not limited to the ic, illustrated embodiments. The
systems for conditioning crystalline particulate materials bed herein are
scalable and adaptable for areas of various size. In particular embodiments,
the s disclosed herein may be scaled-up or scaled-down with regard to,
for example, gas flow rates, active agent mass, material output, desired particle
residence time, etc., ing the desired output rate and the ble space
and equipment. In certain embodiments, the systems disclosed herein may be
assembled as a modular unit and incorporated or built into established
processes and systems for the manufacture of conditioned particulate material,
and are uited for efficient production of conditioned, micronized
particulates. For example, the systems as disclosed here may be incorporated
into commercial milling and micronization ses or a built into a spray
drying system. In further embodiments, the systems described herein may be
operated as part of a batch process where one or more micronized materials
are conditioned and then collected in separate batches. In alternative
ments, the systems described herein may be operated as part of a
continuous feed process whereby one or more micronized materials are
continuously delivered to the system and continuously conditioned and
collected.
III. Methods for conditioning ulate crystalline material
Methods for conditioning particulate crystalline al are also
provided herein. Methods according to the present description can be carried
out using the conditioning systems provided . In general, the methods
described herein include: (1) generating and/or providing a lline
particulate material; (2) introducing the particulate material in an atmosphere
where it is blended with a conditioning gas; (3) maintaining the particulate
material in contact with the conditioning gas for a desired residence time; and
(4) collecting the conditioned particulate material. In specific embodiments, the
particulate material is a micronized crystalline material. Examples of materials
that may be conditioned using the methods described herein include those
materials already described. In particular embodiments of methods according
to the present description, the material to be conditioned is lly entrained
or aerosolized within a delivery gas that is blended with the conditioning gas,
and the particulate material remains entrained, suspended or aerosolized in the
conditioning gas as it travels through the conditioning zone. The nature of the
conditioning gas and the residence time of the ulate material within the
ioning zone are controlled to accomplish annealing of the material.
In specific embodiments, the methods include a continuous
process for micronizing, conditioning, and collecting a crystalline material. In
such embodiments, generating the crystalline al includes subjecting the
al to a micronization s and conditioning of the micronized material
may be conducted in-line with particle collection. Where, the methods
described herein provide in-line or in-process ioning of micronized
material (or, more generally, any size comminuted material), the particulate
material may be blended with a ioning gas and retained within a
conditioning zone to anneal the particulate prior to particle collection.
In other embodiments, methods according to the present
description include primary and secondary conditioning steps. In such
embodiments, the crystalline particulate al can be introduced into (e.g.,
entrained, suspended, or aerosolized within) a first conditioning gas to carry out
a primary annealing and subsequently uced into (e.g., entrained,
suspended, or aerosolized within)a second conditioning gas to carry out a
secondary annealing. Alternatively, for certain materials, a conditioning gas
may be selected that provides substantially simultaneous primary and
secondary annealing of the particulate material. For example, in methods where
primary and secondary ing are d out using a single ioning
gas, the conditioning gas may anneal the ulate material through both
reduction of amorphous content and removal of an undesired al solvent
by vaporization or t replacement.
The methods provided can be tailored to ic materials to be
sed. For example, glycopyrronium is an active agent that can be
conditioning using the systems and methods described herein. Micronization of
crystalline glycopyrronium can lead to a micronized material that includes
significant amorphous content, and in ular embodiments, the present
methods can be adapted to reduce or eliminate amorphous material from
crystalline glycopyrronium particulates. Glycopyrronium conditioned according
to the present description may be in any crystalline form, isomeric form or
mixture of isomeric forms. In this regard, the form of glycopyrronium may be
selected to optimize the activity and/or stability of glycopyrronium. Where
appropriate, glycopyrronium may be provided as a salt (e.g. alkali metal or
amine salts, or as acid addition salts), esters or solvate (hydrates). Suitable
counter ions include, for example, fluoride, chloride, bromide, iodide, nitrate,
sulfate, phosphate, formate, acetate, trifluoroacetate, propionate, butyrate,
lactate, e, tartrate, , maleate, succinate, te, p
chlorobenzoate, diphenyl-acetate or triphenylacetate, o-hydroxybenzoate, p
hydroxybenzoate, oxynaphthalenecarboxylate, 3-hydroxynaphthalene
2-carboxylate, methanesulfonate and benzenesulfonate. In particular
embodiments of the methods described , the bromide salt of
glycopyrronium is used, namely yclopentylhydroxyphenylacetyl)oxy]-1, 1
dimethyl-, bromide). The bromide salt of glycopyrronium is commonly referred
to as glycopyrrolate. Glycopyrrolate is commercially available and can be
prepared according to the procedures set out in U.S. Pat. No. 2,956,062, the
contents of which are incorporated herein by reference.
Where crystalline glycopyrronium, such as crystalline
glycopyrrolate, is the material sed by the methods described herein, the
glycopyrronium material can be ized to exhibit particle size
teristics as described herein, such as, for example, a particle size
distribution le for ary delivery. Moreover, the micronized
glycopyrronium can be prepared and provided using any suitable micronization
technique and delivered into the conditioning chamber via a delivery gas
suitable to the chosen micronization technique. In one such ment, the
glycopyrronium is ized via a jet mill and the delivery gas may be typical
gas flow exiting the jet mill, which would include aerosolized, micronized
particles of glycopyrronium.
In specific embodiments, the bromide salt of glycopyrronium
(glycopyrrolate) may be sed according to the present methods. Where
glycopyrrolate is the material being conditioned, a conditioning gas may be
mixed with a delivery gas (e.g., a jet mill gas flow) in a ratio of about 1 to 4 parts
conditioning gas flow with about 1 part of the delivery gas. In certain such
embodiments, the conditioning gas flow may be mixed with the jet mill gas flow
in a ratio selected from about 1:1, 1.2:1, 1.4:1, 1.6:1, 1.8:1, 2.0:1, 2.2:1, 2.4:1,
2.6:1, 2.8:1, 3:1, 3.2:1, 3.4:1, 3.6:1, 3.8:1, and 4:1. In specific embodiments,
the conditioning gas may be supplied at a gas flow rate ranging from about 150
SCFM up to about 500 SCFM, and the delivery gas may be supplied at a gas
flow rate of g from about 20 SCFM up to about 75 SCFM. However, in
some embodiments, depending on the desired conditions for the conditioning
zone and the nature of the material being processed, the gas flow rate of both
the conditioning gas and the delivery gas may be increased as high as 3,300
SCFM.
When conditioning glycopyrrolate, the conditioning gas may be
delivered at a temperature ranging from about 20 0C to about 30 0C and include
water vapor as a t. In particular embodiments of methods for
conditioning yrrolate, the temperature of the conditioning gas may be
selected from at least 20 0C, 21 C, 22 C, 23 C, 24 C, 25 C, 26 C, 27 C,
28 C, 29 C, and 30 C. Moreover, where ed in the conditioning gas for
ing glycopyrrolate ing to the methods described herein, water
vapor may be provided at a concentration that results in a relative humidity
ranging from about 50% to about 80%. In particular embodiments of methods
for conditioning glycopyrrolate, the conditioning gas may be supplied at a
temperature described herein with a relative humidity selected from at least
about 50%, 51%, 52%, 53%, 54%, 55%, 56%, 57%, 58%, 59%, 60%, 61%,
62%, 63%, 64%, 65%, 66%, 67%, 68%, 69%, 70%, 71%, 72%, 73%, 74% and
75%. At the temperatures and relative humidity described herein, the residence
time of the ized glycopyrrolate material within the conditioning chamber
may be from about 0.5 to about 10 seconds. In certain such embodiments, the
micronized glycopyrrolate material is present within the conditioning chamber
for a residence time selected from about 0.5 seconds, about 1 second, about
1.5 seconds, about 2 seconds, about 2.5 seconds, about 3 seconds, about
3.5 seconds, about 4 s, about 5 seconds, about 6 seconds, about 7
seconds, about 8 seconds, about 9 seconds, and about 10 seconds.
However, the residence time can be ed as needed to achieve the desired
reduction of ous content.
In other embodiments, the s provided can be tailored to for
the annealing of materials soluble in organic solvents. For example, the
methods bed herein can be tailored to the conditioning of corticosteroid
active agents soluble in organic solvents. In certain such embodiments, the
methods bed herein can be tailored for the conditioning of a corticosteroid
selected from fluticasone and budesonide. Fluticasone, pharmaceutically
acceptable salts of fluticasone, such as fluticasone propionate, and preparation
of such materials are known, and described, for e, in U.S. Patent Nos.
4,335,121, 4,187,301, and U.S. Patent Publication No. US2008/125407, the
contents of which are incorporated herein by reference. Budesonide is also well
known and described, for example, in U.S. Patent No. 3,929,768, the contents
of which are incorporated herein by reference.
Micronization of crystalline osteroids, such as budesonide
and fluticasone, can lead to a micronized material that includes significant
amorphous content, and in particular ments, the present methods can
be adapted to reduce or eliminate amorphous material from particulate
crystalline osteroid material. A corticosteroid conditioned according to the
present description may be in any crystalline form, isomeric form or mixture of
isomeric forms. In this regard, the form of the corticosteroid may be selected to
optimize the activity and/or stability of corticosteroid. Where appropriate, the
corticosteroid may be provided as a salt (e.g. alkali metal or amine salts, or as
acid addition salts), esters or e (hydrates).
Where a crystalline corticosteroid material, such as crystalline
fluticasone or budesonide, is the material processed by the methods described
herein, the corticosteroid material can be micronized to exhibit particle size
characteristics as described herein, such as a particle size distribution suitable
for pulmonary delivery. Moreover, the micronized osteroid can be
prepared and provided using any suitable micronization technique and
delivered into the conditioning chamber via a delivery gas suitable to the
chosen micronization technique. In one such embodiment, the selected
corticosteroid is ized via a jet mill and the delivery gas may be l
gas flow exiting the jet mill, which would include lized, micronized
particles of the osteroid.
In ic embodiments, the osteroid to be processed
according to the present methods is selected from fluticasone propionate and
budesonide. In such embodiments, a conditioning gas may be mixed with a
delivery gas (e.g., a jet mill gas flow) in a ratio of about 1 to 4 parts conditioning
gas flow with about 1 part of the delivery gas. In certain such embodiments, the
conditioning gas flow may be mixed with the jet mill gas flow in a ratio selected
from about 1:1, 1.2:1, 1.4:1, 1.6:1, 1.8:1, 2.0:1, 2.2:1, 2.4:1, 2.6:1, 2.8:1, 3:1,
3.2:1, 3.4:1, 3.6:1, 3.8:1, and 4:1. In specific embodiments, the conditioning
gas may be supplied at a gas flow rate ranging from about 150 SCFM up to
about 500 SCFM and the delivery gas may be supplied at a gas flow rate of
ranging from about 20 SCFM up to about 75 SCFM. However, in some
embodiments, depending on the desired conditions for the conditioning zone
and the nature of the material being processed, the gas flow rate of both the
conditioning gas and the delivery gas may be increased as high as 3,300
SCFM.
When conditioning a corticosteroid exhibiting solubility in an
c solvent, such as fluticasone propionate or budesonide, the conditioning
gas may be delivered at a temperature ranging from about 20 OC to about 30 0C
and include an organic solvent vapor as a solvent. In particular embodiments
of methods for conditioning a corticosteroid, ing a corticosteroid selected
from fluticasone propionate and budesonide, the temperature of the
conditioning gas may be selected from at least 20 0C, 21 C, 22 C, 23 C, 24
C, 25 C, 26 C, 27 C, 28 C, 29 C, and 30 C.
Moreover, where included in the conditioning gas, the organic
solvent vapor may be provided within the ioning gas to provide a relative
saturation of the solvent in the conditioning zone ranging from about 10% to
about 95%. Suitable organic solvents include an l (e.g., ethanol,
methanol, isopropyl alcohol, etc.), ketone (e.g., acetone, methyl ketone, ethyl
ketone, etc.), ester (e.g., ethyl acetate, etc.), aliphatic alcohol (e.g., octanol,
etc.), or alkane (e.g., octane, nonane, etc.). In specific embodiments for the
conditioning of corticosteroid materials, including corticosteroids ed from
fluticasone propionate and budesonide, the c solvent vapor may be
provided within the conditioning gas to e a relative saturation of the
solvent in the conditioning zone ranging from about 50% to about 80%. For
example, in ments of methods for conditioning corticosteroid materials,
including corticosteroids selected from asone propionate and budesonide,
the conditioning gas may be supplied at a temperature described herein with a
relative solvent saturation ed from at least about 50%, 51%, 52%, 53%,
54%, 55%, 56%, 57%, 58%, 59%, 60%, 61%, 62%, 63%, 64%, 65%, 66%,
67%, 68%, 69%, 70%, 71%, 72%, 73%, 74% and 75%. At the temperatures
and relative solvent saturation described herein, the residence time of the
micronized corticosteroid material within the conditioning chamber may be from
about 0.5 to about 10 seconds. In certain such embodiments, the micronized
corticosteroid material is present within the conditioning chamber for a
residence time selected from about 0.5 seconds, about 1 second, about 1.5
seconds, about 2 seconds, about 2.5 seconds, about 3 seconds, about 3.5
seconds, about 4 seconds, about 5 seconds, about 6 seconds, about 7
seconds, about 8 seconds, about 9 seconds, and about 10 seconds.
However, the residence time can be adjusted as needed to achieve the desired
ioning.
As is further evidenced by the experimental examples that ,
methods according to the present description can be adapted to accomplish
conditioning of varying materials exhibiting divergent physical and chemical
properties.
IV. Exemplary Embodiments
In specific ments, methods for conditioning a particulate
crystalline material (e.g., micronized crystalline material) according to the
present description include: providing aerosolized micronized crystalline
particles, wherein said micronized crystalline particles contain one or both of an
amorphous material and a residual solvent; continuously mixing the micronized
lline particles with a conditioning gas comprising a r gas and a
conditioning vapor in a chamber connected directly to the exit of a micronization
apparatus; maintaining the micronized crystalline particles in contact with the
conditioning gas for sufficient time to result in annealing of said micronized
crystalline particles, wherein said annealing results in a phase transformation;
and separating the micronized crystalline particles from the conditioning gas.
As detailed herein, such a phase transformation refers to a change in the bulk
of the crystals present in a particulate crystalline material. In such
embodiments, the phase transformation may be selected from removal of a
solvent of crystallization, ement of a solvent of crystallization, an
amorphous to crystalline phase , or a change in physical structure
beyond just an amorphous to crystalline phase change.
The al (e.g., micronized crystalline material) processed
according to any method described herein may be mixed with the conditioning
gas for between about 0.1 to 600 seconds before the micronized lline
material exits the conditioning zone.
The al (e.g., micronized crystalline al) sed
ing to any method described herein may be mixed with the conditioning
gas for between about 2 to 6 seconds before the material exits the conditioning
zone.
The material (e.g., micronized crystalline material) processed
according to any method described herein may be mixed with the conditioning
gas for about 3 seconds before the micronized crystalline al exits the
conditioning zone.
The material (e.g., micronized crystalline material) processed
according to methods described herein may be water soluble. Where the
material to be processed according to a method described herein is water
soluble, the conditioning gas may include a solvent vapor that is an aqueous
solvent vapor, and the conditioning gas may be provided at a temperature
ranging from about 20 0C to 100 0C and at a relative humidity g from
about 0.05% to 95%.
The material (e.g., micronized crystalline material) processed
according methods bed herein may not be water soluble (e.g., soluble in
one or more organic solvents). Where the al to be sed according
to a method described herein is not water soluble the conditioning gas may
include a solvent vapor that is an organic solvent vapor, and the conditioning
gas may be provided at a temperature ranging from about 20 0C to 100 0C and
at a vapor pressure of a non-aqueous solvent in the range of about 0.05% to
95%.
The material (e.g., micronized crystalline material) processed
according to methods bed herein may be an admixture of water soluble
and non-water soluble materials. In such instances, the conditioning gas may
include a solvent vapor that includes an aqueous solvent vapor and an organic
t vapor, and the conditioning gas may be supplied at a temperature
ranging from about 10 0C to 100 0C and at a relative ty of the aqueous
solvent in the range of about 0.05% to 95% and a vapor re of the non
aqueous solvent in the range of about 0.05% to 95%.
In any of the methods described herein, the material (e.g.,
micronized lline al) to be processed may be entrained, suspended,
or aerosolized within a delivery gas before mixing with a conditioning gas. In
such embodiments, the material may be ed using a jet mill and
aerosolized in the jet mill gas flow.
In any of the embodiments of the methods and systems described
, the conditioning gas may be mixed with the particulate material (e.g., an
aerosolized micronized crystalline material) in a ratio of about 1 to 10 parts
conditioning gas with about 1 part of the aerosolized micronized lline
material. In such embodiments, the aerosolized micronized crystalline material
may be ned, suspended or aerosolized within a delivery gas.
In any of the embodiments of the systems and methods described
herein, the conditioning gas may be supplied at a flow rate ranging from about
standard cubic feet per minute (SCFM) up to about 300 SCFM while mixing
with the particulate crystalline material.
In any of the embodiments of the systems and methods described
herein, the particulate material (e.g., micronized crystalline material) may be
entrained, ded or lized within a ry gas and the aerosolized
particulate material supplied at a flow rate ranging from about 25 standard cubic
feet per minute (SCFM) up to about 200 SCFM while mixing with a ioning
gas.
In any of the embodiments of the systems and s described
herein, the conditioning gas may comprise nitrogen gas.
In any of the embodiments of the systems and methods described
herein, the particulate material (e.g., micronized lline material) may be
mixed with the conditioning gas in a closed chamber.
In any of the embodiments of the systems and methods described
herein, the particulate material (e.g., micronized crystalline al) may be
one of glycopyrronium, including glycopyrrolate, dexipirronium, scopolamine,
tropicamide, pirenzepine, dimenhydrinate, tiotropium, darotropium, aclidinium,
umeclidinium, trospium, ipatropium, atropine, benzatropin, oxitropium,
ephedrine, adrenaline, fenoterol, formoterol, isoprenaline, metaproterenol,
salbutamol, albuterol, salmeterol, terbutaline, fluticasone, including fluticasone
propionate, budesonide, mometasone, ciclesonide, and Compound A.
In specific embodiments, systems for conditioning a particulate
crystalline material (e.g., ized crystalline al) according to the
t description include: a ry zone for delivering the particulate
material; a mixing zone in fluid communication with the ry zone, wherein
the particulate crystalline al is delivered from the micronizing zone to the
mixing zone and therein mixed with a conditioning gas; a conditioning gas
supply zone in fluid communication with the mixing zone, the conditioning gas
supply zone ing the conditioning gas at a desired temperature and
solvent vapor concentration to the mixing zone to be mixed with the particulate
crystalline material; a conditioning zone in fluid communication with the mixing
zone, wherein the mixture of the particulate crystalline al and the
conditioning gas is delivered and remains in the conditioning zone for a desired
residence time; and a separation and collection zone, wherein the conditioned
particulate crystalline material is separated from the conditioning gas and the
ioned material is collected. In certain such embodiments, the delivery
zone may be a micronizing zone comprising a device for micronizing the
particulate crystalline material.
In particular embodiments, the systems described herein are
configured to process a particulate crystalline material (e.g., micronized
lline material) that is water soluble and the conditioning gas supply zone
is configured to provide a conditioning gas that includes a water vapor at a
temperature ranging from about 20 0C to 100 0C and at a humidity g from
about 0.05% to 90% relative humidity.
In particular embodiments, the systems described herein are
configured to process a particulate crystalline material (e.g., micronized
crystalline material) that is not water soluble and the conditioning gas supply
zone is configured to provide a conditioning gas that includes an non-aqueous
(e.g. an organic solvent as described herein) vapor at a temperature ranging
from about 20 0C to 100 0C and at a vapor pressure of a ueous solvent
in the range of about 0.05% to 90%.
In particular embodiments, the systems described herein are
configured to process a particulate crystalline material (e.g., micronized
crystalline material) that is an admixture of water soluble and non-water soluble
materials, and the conditioning gas supply zone is configured to provide the
conditioning gas at a temperature ranging from about 20 0C to 30 0C and at a
relative humidity of 50 to 75% and vapor re of a non-aqueous solvent in
the range of about 50% to 75%.
In any of the ments described herein, the system for
conditioning particulate material may include a conditioning gas supply zone
configured to e a conditioning gas at a temperature of about 25 0C and
with a humidity of about 65% relative humidity
In any of the embodiments described herein, the system for
ioning ulate material may include a conditioning zone configured to
maintain the mixture of the particulate material (e.g., micronized crystalline
material) and the conditioning gas within the conditioning zone for a residence
time of n about 0.5 to 60 seconds. For e, the systems for
conditioning particulate material described herein may include a conditioning
zone configured to maintain a mixture of the particulate crystalline al and
the conditioning gas within the conditioning zone for a residence time of
between about 1 to about 10 seconds. In even more specific embodiments, the
systems for conditioning particulate material described herein may include a
ioning zone configured to maintain a mixture of the particulate crystalline
material and the conditioning gas within the conditioning zone for a residence
time of about 3 seconds.
In any of the embodiments described herein including a delivery
zone that ses a device for micronizing the particulate crystalline material
(i.e., a micronizing zone), the device for micronizing the particulate crystalline
material may be a jet mill or any other suitable system or device as described
herein.
In any of the embodiments described herein, the systems for
conditioning a particulate material may be configured for ioning a material
selected from a particulate crystalline material (e.g., micronized crystalline
material) ed from at least one of glycopyrronium, including glycopyrrolate,
dexipirronium, scopolamine, tropicamide, pirenzepine, dimenhydrinate,
tiotropium, darotropium, aclidinium, umeclidinium, trospium, ipatropium,
atropine, benzatropin, oxitropium, ephedrine, adrenaline, fenoterol, formoterol,
isoprenaline, metaproterenol, salbutamol, albuterol, salmeterol, terbutaline,
fluticasone, ing fluticasone propionate, budesonide, mometasone,
ciclesonide, and Compound A.
In particular embodiments of the systems described , the
systems may be configured for conditioning a particulate glycopyrrolate material
using any of the process conditions detailed herein. In certain such
embodiments, the s described herein can be configured for micronizing
a crystalline glycopyrrolate material. In such embodiments, the systems may
e a micronizing zone with a jet mill for micronizing glycopyrrolate. In
certain such ments, the jet mill gas may be a delivery gas and mixed
with a conditioning gas within the mixing zone at a ratio of from about 1 to 4
parts conditioning gas mixed with about 1 part of the jet mill gas.
In any of the embodiments described herein, the systems for
conditioning a particulate lline al (e.g., micronized crystalline
material) may include a conditioning gas supply zone configured to provide the
conditioning gas to the mixing zone at a flow rate ranging from about 150
standard cubic feet per minute (SCFM) up to about 300 SCFM.
In any of the embodiments described herein, the s for
conditioning a particulate crystalline material (e.g., micronized crystalline
material) may be configured to entrain, suspend, or aerosolize the particulate
material within a delivery gas before the material is introduced to a mixing zone
or blended with a conditioning gas. In any of the embodiments described
herein, the s for conditioning a particulate crystalline material (e.g.,
micronized crystalline material) may be configured to deliver the particulate
material in a delivery gas at a flow rate ranging from about 35 standard cubic
feet per minute (SCFM) up to about 200 SCFM.
In any of the embodiments described , the systems for
conditioning a particulate crystalline material (e.g., micronized crystalline
material) may be ured to include a mixing zone that comprises a
dispersion head assembly wherein the conditioning gas and the micronized
crystalline material are mixed. In such embodiments, the dispersion head
assembly may include a mixing head configured to control the mixing of the
conditioning gas and the particulate crystalline material. Where a system as
described herein includes a mixing head, the mixing head may be configured to
include an injection nozzle inlet ured to deliver the conditioning gas to an
injection nozzle and a delivery gas inlet configured to deliver the micronized
crystalline material to the injection nozzle.
In any of the embodiments described herein, the systems for
conditioning a particulate crystalline material (e.g., ized crystalline
material) the collection zone may e a cyclone collector.
In any of the embodiments described herein, the systems for
conditioning a particulate crystalline material (e.g., micronized crystalline
al), the system may be ured to process ized crystalline
material having a particle size ranging from about 0.1 pm to about 10 pm.
In any of the embodiments described herein, the systems for
conditioning a ulate crystalline material (e.g., micronized crystalline
material), the system may include a holding chamber for collecting the
conditioned particles. In n such embodiments, the system may be
configured to prepare and/or deliver a secondary conditioning gas to the
holding chamber and mix the ary conditioning gas with the conditioned
crystalline particles within in the holding chamber for a period of time sufficient
to provide a secondary conditioning of the lline particles. Alternatively, in
embodiments of a system for conditioning a particulate crystalline material that
e a holding chamber, the holding chamber may be configured simply to
receive the conditioned material or to facilitate transition of the conditioned
material from a primary conditioning system to a secondary conditioning
system. In any of the embodiments of the systems described herein that
include a holding chamber, the g chamber may be ured to maintain
the conditioned material in a continuously fluidized state.
EXPERIMENTAL EXAMPLES
EXAMPLE 1
Glycopyrrolate yclopentylhydroxyphenylacetyl)oxy]-1, 1
dimethyl-, bromide) was ed as coarse crystalline active agent from the
manufacturer (Boehringer Ingelheim Chemicals, Inc., Petersburg, VA 23805).
The glycopyrrolate (GP) was then micronized by jet milling to achieve a
reduction in particle size distribution.
A portion of the micronized GP was also conditioned using an in
process conditioning system wherein nitrogen conditioning gas was supplied to
the in-process conditioning system and was controlled for flow rate,
temperature and humidity. The conditioning gas was humidified h a
droplet ation chamber after which it was directed to a mixing zone. In
the mixing zone, the conditioning gas was mixed with the lled aerosol
comprising the micronized GP. The aerosol then entered a conditioning zone
where annealing of the micronized GP occurred. The particle residence time
through the conditioning zone was adjusted by means of the conditioning zone
chamber geometry and/or the gas flow rate through the conditioning zone
chamber. After passing through the conditioning zone, the micronized GP
particles reached the cyclone-collection zone where the solid les were
separated from the gas phase and transported to a collection vessel. Upon
completion of the batch processing, the collector was aged and
transferred to a glove box for sampling. The sampling occurred in a <5%
relative ty environment. Samples were then analyzed for particle size
distribution and ous content.
The particle size distribution of the standard jet milled micronized
GP particles and the micronized GP particles after cess conditioning were
sampled and are shown in Table 1. The particle size distributions in Table 1
reflect the GP particle sizes sampled immediately after processing. As is
shown in Table 1, the in-process conditioning does not affect the particle size
distribution of the ized GP particles.
2014/029489
Table 1: Comparison of micronized GP le size distributions
Particle Size Distribution of Micronized GP
Process X10 X50 X90 Span
(pm) (pm) (pm) ((X90-X10)/X50)
Standard Jet Milling 0.5 1.4 3.0 1.7
In-Process 0.6 1.5 3.1 1.7
Conditioning
Experimental batches of micronized GP les were ed
according to the in-process ioning system as described herein. The jet
milling parameters and the conditioning parameters used for the in-process
conditioning for each of the experimental batches are shown in Table 2. Batch
1A was a control batch of standard micronized GP and was not ioned but
was processed using dry nitrogen gas at ambient temperature. The powder
feed rate for all batches were set nominally at 66 g/hr.
Table 2: Micronized GP in-process conditioning parameters
Jet Milling ters Conditioning Parameters
Conditioning
Batch # Gas Temp Feed Grind Jet Mill Conditioning Approx.
(0C/%RH) Pressure Pressure Gas Flow Gas Flow CMR Residence
(psi) (psi) L in) (std L/min) Time (sec)
1A Ambient /0 82 75 122 265 2.2:1 2.9
2B 250/35 82 75 122 265 2.2:1 2.9
2C 250/65 82 75 122 265 2.2:1 2.9
2D 250/65 82 75 122 166 1.4:1 3.8
2E 26/51 82 75 122 265 2.2:1 2.9
2F 280/67 82 75 122 265 2.2:1 2.9
2G 240/64 82 75 122 166 1.4:1 3.8
Table 3 lists the particle size distribution for the experimental
batches as was determined by laser diffraction immediately after processing
and again after 1-day of exposure to 250C and 60% relative humidity.
2014/029489
Table 3: le size distributions initial and post-exposure
% Particle Size Distribution Particle Size Distribution
Batch # Amorphous Initial Post-exposure al
Content X10 X50 X90 Span X10 X50 X90 Span Stability
Initial (pm) (pm) (pm) (pm) (pm) (pm) (pm) (pm)
1A 17.9% 0.6 1.5 3.1 1.7 0.9 3.4 13.3 3.6 Unstable,
Unstable,
2B 5.3% 0.6 1.6 3.1 1.6 0.7 2.0 3.6 1.4 lly
fused
2C 0.9% 0.6 1.5 2.8 1.5 0.6 1.6 2.9 1.5 ,
I I no fusing
2D 0.9% 0.6 1.5 2.7 1.4 0.6 1.5 2.8 1.5 Stable,
no fusing
2E 2.6% 0.5 1.3 2.6 1.6 0.5 1.4 2.7 1.5 Stable,
Ino fusing
2F 0.9% 0.6 1.5 2.8 1.5 0.6 1.6 2.9 1.5 Stable,
no fusing
2G 2.3% 0.5 1.4 2.7 1.6 0.6 1.5 2.9 1.5 Stable,
2G_________________ 2.3%___0.5_1__4_2__7_ no fusing 1
As shown in Figure 5, analysis of the particle size distribution of
the 1A control batch confirms the instability of the standard micronized GP as
evidenced by the significant increase in particle size distribution of the
micronized GP particles after 1-day re.
Figure 6A is an electron micrograph of the 1A control sample
before exposure showing an amorphous logy with rough surfaces and
edges and increased shape variability. Figure 6B is an electron micrograph of
the 1A control sample after exposure showing that the unstable amorphous
micronized GP material leads to fusing and agglomeration of the micronized GP
particles.
In contrast, analysis of the 2D batch that was conditioned
according to the cess conditioning parameters as listed in Table 2,
showed particle size stability. As shown in Figure 7, the particle size
distribution was essentially identical for the initial sampling and after the 1-day
exposure at 250C and 60% relative humidity. Similar s were observed for
the stability of the particle size distribution for the 2C, 2E, 2F, and the 2G
samples (not shown).
WO 44894
Electron micrographs of the cess conditioned sample 2E
show improved stability of conditioned micronized GP particles. As shown in
Figure 8A, the conditioned micronized GP particles show a crystalline
morphology with smooth surfaces and distinct edges. As seen in Figure 8B, the
ioned micronized GP particles show improved stability with no fusing and
agglomeration even after exposure to heat and humidity. Accordingly, the in
process conditioning system disclosed herein improves micronized GP particle
stability and prevents particle fusing and agglomeration.
EXAMPLES 2 & 3
Examples 2 and 3 provide examples of in-process conditioning of
water ble les using a conditioning gas containing a vaporized
c solvent (ethanol) to promote annealing. Budesonide and fluticasone
propionate were selected as representative compounds. The ing
conditions were determined by selecting conditions that would promote
crystallization of the ous fraction under an ethanol atmosphere by
determining the corresponding ethanol sorption isotherms.
Budesonide (16,17-(butylidenebis(oxy))-11,21-dihydroxy-, (11
p,16-a)-pregna-1,4-diene-3,20-dionel6,17-(butylidenebis(oxy))-11,21
dihydroxy-, (11-6,16-a)-pregna-1,4-diene-3,20-dione) was micronized using a
laboratory scale jet mill set at 75 psig grinding re and 80 psig injection
pressure. The lline budesonide was fed into the jet mill at a powder feed
rate of approximately 25 ± 10% g/hr. Two batches of micronized budesonide
were produced. One was not subjected to further processing, while the second
was conditioned to remove amorphous content according to the present
description.
Batch 1 (unannealed/not conditioned) did not undergo any
thermal or vapor conditioning. The nitrogen gas was supplied dry to the system
(i.e., no organic solvents were used), and the micronized material was collected
under at ambient temperature. Batch 1 was collected and transferred into a
purged isolator for sampling.
Batch 2 (annealed/conditioned) was conditioned according to the
present description using a conditioning gas that included an ethanol vapor,
with a target of 75% relative saturation in the conditioning zone. To form the
conditioning gas, ethanol (95% w/w) was ed in nitrogen gas using a 0.21"
atomizer nozzle with a set atomizer gas flow rate of 30 std. L/min (SLPM) and a
liquid flow rate of 32 g/min. The conditioning gas flow rate was set to 205
SLPM with a humidifier inlet temperature of 1850C and conditioning zone outlet
of 300C. The jet mill grind pressure was delivered at 75 psig with an injection
pressure of 80 psig, resulting in a nominal micronizer gas flow rate of 122
SLPM, along with a total conditioning gas flow rate (including the atomizer gas
flow) of 235 SLPM. The conditioning gas to izing gas (also ed to as
a ry gas) ratio (CMR) for this process configuration was 1.9:1, with a
nominal total system gas flow rate of 357 SLPM. Batch 2 was collected in a
0.5L stainless steel collector, transferred to a purged (<5% RH) isolator and
sampled for analysis.
Both batches of micronized budesonide were analyzed for particle
size distribution by Sympatec laser diffraction, with the results provided in Table
4. As can be seen in Table 4, Batch 2 (annealed) demonstrated good physical
stability after micronization, whereas Batch 1 (unannealed) demonstrated
potential agglomeration marked by a significant shift in size distribution.
Table 4: le Size Distribution of Micronized nide.
D10 D50 D90
Micronized Budesonide (pm) (pm) (pm) Span
Batch 1 (unannealed) 0.6 2.3 5.4 2.1
Batch 2 (annealed) 0.5 1.2 2.5 1.7
The amorphous content by vapor sorption and particle
morphology for both batches were also assessed. Figure 9 provides the
l vapor sorption isotherm at 250C for both batches of micronized
budesonide. As can be seen in Figure 9, Batch 1 (unannealed, top) remained
substantially amorphous (weight loss at 60% p/po), while Batch 2 (annealed,
bottom) was stable and showed no crystallization event. Figure 10 provides
SEM imaging of the material from Batch 1 and Batch 2, and as can be seen by
reference to Figure 10, the annealed material of Batch 2 (right) presented
smoother surfaces and more rounded edges than the unannealed material of
Batch 1 (left).
EXAMPLE 3
Fluticasone propionate (S-(fluoromethyl)-6a,9-difluoro-11p, 17
oxy-16a-methyloxoandrosta-1, 4-diene-17p-carbothioate, 17
propanoate) was micronized using a laboratory scale jet mill set at 65 psig
grinding pressure and 74 psig injection re. The crystalline fluticasone
was fed into the jet mill at a powder feed rate of approximately 25 ± 10% g/hr.
Two s of micronized fluticasone were ed. One was not subjected
to further processing, while the second was ioned to remove amorphous
t according to the present description.
Batch 1 (unannealed/not conditioned) did not undergo any
thermal or vapor conditioning. The nitrogen gas was supplied dry to the system
(i.e., no organic solvents were used), and the micronized material was collected
under at ambient temperature. Batch 1 was collected and erred into a
purged isolator for sampling.
Batch 2 (annealed/conditioned) was conditioned according to the
present description using a conditioning gas that included an ethanol vapor,
with a target of 75% ve saturation in the conditioning zone. To form the
conditioning gas, ethanol (95% w/w) was atomized in nitrogen gas using a 0.21"
atomizer nozzle with a set atomizer gas flow rate of 30 std. L/min (SLPM) and a
liquid flow rate of 32 g/min. The conditioning gas flow rate was set to 205
SLPM with a humidifier inlet temperature of 1850C and conditioning zone outlet
of 300C. At the given grind and ion pressures red to the system, the
resulting micronizer gas flow was nominally 108 SLPM , along with a total
WO 44894
conditioning gas flow rate (including the atomizer gas flow) of 235 SLPM. The
ioning gas to micronizing gas (also referred to as a delivery gas) ratio
(CMR) for this process was 2.2:1, with a total gas flow of 343 SLPM. Batch 2
was collected in a 0.5L stainless steel collector, transferred to a purged (<5%
RH) isolator and sampled for analysis.
Both batches of micronized fluticasone were analyzed for particle
size distribution by Sympatec laser diffraction, with the results provided in Table
. As can be seen in Table 5, Batch 2 (annealed) trated good physical
stability after micronization, whereas Batch 1 (unannealed) demonstrated
agglomeration marked by a shift in size distribution.
Table 5: Particle Size Distribution of Micronized Fluticasone Propionate.
D10 D50 D90
Micronized Fluticasone propionate (pm) (pm) (pm) Span
Batch 1 (unannealed) 0.5 1.5 3.4 2.0
Batch 2 (annealed) 0.5 1.4 3.1 1.9
The amorphous content by vapor sorption and particle
morphology for both batches were also assessed. Figure 11 provides the
ethanol vapor sorption isotherm at 250C for both batches of micronized
fluticasone. As can be seen in Figure 11, Batch 1 (unannealed, top) remained
substantially amorphous (weight loss at 60% p/po), while Batch 2 (annealed,
bottom) was stable and showed no crystallization event. Figure 12 provides
SEM g of the material from Batch 1 and Batch 2, and as can be seen by
nce to Figure 10, the annealed al of Batch 2 (right) presented
smoother surfaces and more rounded edges than the unannealed material of
Batch 1 (left).
EXAMPLE 4
Three up batches of micronized glycopyrrolate (GP) were
produced via a large-scale in-process micronization and conditioning system
according to the present description that utilized a llector process at
approximately 1 kg per batch. The first two lots were manufactured using a
single, raw crystalline API lot, while the third used a different lot from the same
vendor. All batches were produced on different dates using the same process
configuration that utilized the same 4" jet mill, and the same conditioning
environment (i.e., a target of 55% RH at 400C conditioning zone outlet
temperature).
The system was brought to steady-state equilibrium, with the jet
mill ing at 68 psig injection pressure and 48 psig grind pressure for a
micronizer gas flow of approximately 36 SCFM. Again, the micronizer gas also
served as the delivery gas for the ized material. The conditioning gas
flow rate was supplied at approximately 78 SCFM with a humidifier outlet
temperature of 570C. Water was red to the 0.21" atomizer nozzle at a
liquid flow rate of 75.1 ml/min. The ioning to micronization gas ratio
(CMR) was set at 2.2:1. Product was collected in 8L stainless steel collectors,
which were heated using a thermal jacket to prevent the collector environment
from falling below the dew-point temperature.
Once the system reached steady-state, powder was fed into the
jet mill at a nominal rate of 1 kg/hr. A collector -out was performed half
way through each run with a collector purging step before each change-out to
obviate the risk of any post-process affects due to residual vapor. The
collectors were transferred to a purged isolator (<5% RH) for ng and
packaging to prevent any post-process affects due to ambient moisture.
All batches were analyzed for le size distribution by
Sympatec laser ction, with the results provided in Table 6. n=3 replicates
per collector were assessed (mean values are shown). As can be seen in
Table 6, the le size distribution achieved in each batch exhibited good
batch to batch reproducibility.
Table 6: Particle Size Distribution of Micron ized/Annealed GP
Micronized/Annealed D10 D50 D90
Glycopyrrolate (pm) (pm) (pm) Span
Batch A - Collector 1 0.52 1.48 3.02 1.68
Batch A - Collector 2 0.52 1.47 2.99 1.69
Batch B - Collector 1 0.52 1.47 3.02 1.70
Batch B - Collector 2 0.52 1.46 2.99 1.70
Batch C - tor 1 0.52 1.47 3.03 1.70
Batch C - Collector 2 0.51 1.45 2.96 1.69
All batches were also analyzed for amorphous content by
dynamic vapor sorption using n=2 ates per collector. The results are
provided in Table 7, which reflects that the amorphous t achieved in
each batch also exhibited good batch to batch reproducibility.
Table 7: Amorphous Content of Conditioned GP
Calculated Calculated
Micronized/Annealed Amorphous t, Amorphous Content,
GP Collector 1 Collector 2
Batch A 2.65% 2.35%
Batch B 2.65% 2.40%
Batch C 2.65% 2.45%
EXAMPLE 5
Sucrose (saccharose; a-D-glucopyranosyl-(1 -D
furanoside) was micronized and conditioned using the large scale
micronization/annealing system utilized in e 4. Particulate sucrose was
delivered to the 4" jet mill at a nominal powder feed rate of 0.5 kg/hr. Two
batches of micronized sucrose were produced. For the first, the 4" jet mill was
set at an 80 psig injection pressure and a grind pressure of 70 psig. For the
second, the 4" jet mill was set at an 80 psig injection pressure and a grind
pressure of 76 psig. Identical lots of the raw input material were used for
dispensing both batches. Process conditions for each batch are provided in
Table 8.
e A (unannealed/not conditioned) did not undergo any
thermal or vapor conditioning. The nitrogen gas was supplied dry to the system,
and the system was run at ambient temperature. The jet mill was operated at
80 psig injection pressure and 70 psig grind pressure for a nominal micronizer
gas flow of approximately 45.0 SCFM. The conditioning gas flow rate (ambient
WO 44894
temperature, 0 %RH) was supplied at approximately 61.0 SCFM. The
conditioning to micronizing gas Ratio (CMR) was set at 1.4:1. Product was
collected in 8L stainless steel collectors, without the use of a thermal jacket.
Powder was fed into the jet mill at a nominal feed rate of 0.5 kg/hr.
A collector change-out was performed half way through each run. The
collectors were transferred to a purged isolator (<5% RH) for sampling and
packaging to t any post-process affects due to ambient moisture.
Sucrose B (annealed/conditioned) was conditioned at a target
55% ve humidity at 400C conditioning zone outlet temperature. The
system was t to steady-state equilibrium, with the jet mill operating at 80
psig injection pressure and 76 psig grind pressure for a nominal micronizer gas
flow of approximately 49.4 SCFM. The conditioning gas flow rate was supplied
at imately 61.8 SCFM with a humidifier outlet temperature of 157.20C.
Water was delivered to a 0.21" atomizer nozzle at a liquid flow rate of 76.2
. The conditioning to izing gas Ratio (CMR) was set at 1.4:1.
Product was collected in 8L stainless steel collectors, which were heated using
a thermal jacket to prevent the collector environment from falling below the
dew-point temperature.
Once the system reached steady state, powder was fed into the
jet mill at a rate of 0.5 kg/hr. A collector change-out was performed half way
through each run, including a system purge-out step prior to each change-out to
obviate the risk of any post-process s due to residual vapor. The
tors were erred to a purged isolator (<5% RH) for sampling and
packaging to prevent any post-process affects due to ambient moisture.
Table 8: Process Conditions for Production of Micronized Sucrose Batches.
Nominal Approx.
Powder Jet Mill Jet Mill Nominal Nominal Liquid
Feed Grind Injection Micronizer Conditioning Flow Target
Batch Rate Pressure Pressure Flow Rate CMR Gas Flow Rate Rate Conditioning
# kg/hr psi psi SCFM - SCFM ml/min 'C/%RH
Sucrose A 0.5 70 80 45.2 1.4 61.0 N/A 18/0
Sucrose B 0.5 76 80 49.4 1.4 61.8 76.2 40/55
WO 44894
Both micronized sucrose batches were analyzed for particle size
distribution by Sympatec laser diffraction. The results of the analysis are
provided in Table 9 and Figure 15. Sucrose A was not tested after exposure,
however fusing of the material on ity was med by visual observation,
demonstrating an unstable powder. Sucrose B was exposed to a 250C/60%
RH environment and showed good stability even post-exposure. Figure 15
shows the particle size distribution ed in Sucrose B after it was freshly
made and then after exposed to a 250C/60%RH environment.
Table 9: Particle Size Distribution of ized Sucrose
Particle Size Distribution Particle Size Distribution
Initial T=1 day at 250C/60%RH Physical
Batch #___RH Pyia
X10 X50 X90 Span X10 X50 X90 Span ity
(pm) (pm) (pm) (pm) (pm) (pm) (pm) (pm)
Sucrose 1 0.5 1.7 4.5 2.4 NT NT NT NT Unstable,
Sucrose 2 0.6 2.2 4.9 1.9 0.7 2.5 5.2 1.9 Stable,
____ ____no____ __ _ ___ fusing
The amorphous content by vapor sorption and particle
morphology for both batches of micronized sucrose were also assessed.
Figure 13 provides the water vapor sorption isotherm at 250C for both batches
of ized sucrose. As can be seen in Figure 13, Sucrose A (unannealed,
top) remained substantially amorphous (weight loss at 30% p/po), while Sucrose
B (annealed, bottom) was stable and showed no crystallization event. Figure
14 provides SEM imaging of the material from Sucrose A and Sucrose B, and
as can be seen by reference to Figure 14, the annealed material of Sucrose B
(right) presented er surfaces and more rounded edges than the
unannealed al of Sucrose A (left).
EXAMPLE 6
nd A, a novel bi-functional muscarinic antagonist and
beta2 agonist (IUPAC: 7-[(1 R)[2-[2-fluoro[[4-(2-isopropylthiazole-4
carbonyl)-1 -oxa-4,9-diazaspiro[5.5]undecanyl]methyl]phenyl]ethylamino]-1
hydroxy-ethyl]hydroxy-3H-1,3-benzothiazolone; di[[(1S,4R)-7,7-dimethyl
2-oxo-norbornanyl]methanesulfonic acid] salt), was selected for
micronization and subsequent solvent removal using primary and secondary
conditioning steps. Compound A retained -5% residual isopropyl alcohol
solvent after manufacture. Compound A was micronized and conditioned using
an in-process conditioning system according to the present description that
included a 1" jet mill. Process conditions were selected to promote solvent
exchange to reduce or remove residual pyl alcohol and replace the
isopropyl alcohol either directly with water or with ethanol and secondarily with
water. Three batches of micronized Compound A were produced as described
in Table 10 below. Identical lots of the raw input al were used for
dispensing all three batches.
Table 10
Nominal Jet Mill Jet Mill %
Powder Grind Injection Relative Batch
Batch Description Feed rate Pressure Pressure Temp Sat. Yields
-g/hr psi psi C % RS %
No Conditioning 25 ± 2 70 80 21 0 49%
29'C/69% RH 25 ±2 70 80 29 69 62%
30C/53% RS (ethanol) 25 ± 2 70 80 30 53 53%
Batch 1 (unannealed) did not undergo any thermal or vapor
conditioning. The nitrogen gas was supplied dry to the system and ran at
ambient temperature (i.e., no heat or t vapor was used). The total
ioning gas flow rate was 255 SLPM. The micronization gas flow rate was
about 110 SLPM at the given milling res, giving a ioning to
micronization gas Ratio (CMR) of 2.3:1 and total gas flow of 365 SLPM. Batch 1
was collected and transferred into a purged isolator for sampling.
Batch 2 (conditioned with water vapor at 29 0C/69%RH) was
conditioned using a conditioning gas that provided water vapor at 69% relative
humidity (RH) in the ioning zone. The conditioning gas was formed by
ing water in nitrogen gas using a 0.21" atomizer nozzle, with a set
er gas flow rate of 35 std. L/min (SLPM) and a liquid flow rate of 7 g/min.
The conditioning gas flow rate was set to 220 SLPM with a humidifier inlet
temperature of 1000C and conditioning zone outlet of 290C. The total
conditioning gas flow rate including the atomizer was 255 SLPM. The
micronization gas flow rate was about 110 SLPM at the given milling pressures,
giving a ioning to micronization gas Ratio (CMR) of 2.3:1 and total gas
flow of 365 SLPM. Batch 2 was collected in a 0.5L stainless steel collector,
transferred to a purged (<5% RH) isolator and sampled for analysis.
Batch 3 (primary conditioning with l at 300C/53%RS;
secondary conditioning with water at 7%RH) was conditioned using a
conditioning gas including ethanol vapor, with a target of 75% relative
saturation in the conditioning zone. The conditioning gas was formed by
atomizing l (95% w/w) in nitrogen gas using a 0.21" atomizer nozzle, with
a set atomizer gas flow rate of 35 std. L/min (SLPM) and a liquid flow rate of 28
g/min. The conditioning gas flow rate was set to 220 SLPM with a humidifier
inlet temperature of 1500C and ioning zone outlet of 300C. The
micronization gas flow rate was about 110 SLPM at the given g pressures,
giving a conditioning to micronization gas Ratio (CMR) of 2.3:1 and total gas
flow of 365 SLPM. Upon completion of conditioning with ethanol, ethanol liquid
flow was stopped, and the process was adjusted to provide a conditioning gas
containing water vapor. The humidifier inlet temperature of 1000C was set and
water was then fed into the system at a flow rate of 7 g/min at a CZ outlet
temperature and collector temperature of 300C. The material was secondarily
conditioned in the collector with a conditioning gas ning water vapor at 67
%RH. Batch 3 was collected in a 0.5L stainless steel collector, transferred to a
purged (<5% RH) isolator and sampled for analysis.
All three batches were analyzed for particle size distribution by
ec laser diffraction, with the results shown in Table 11. Particle Size
Distribution of conditioned Compound A demonstrates good reproducibility, and
the particle size bution of the conditioned Compound A is consistent with
the unannealed micronized material.
Table 11
D10 D50 D90
Compound A, PSD (pm) (Pm) (pm)
Raw (Un-milled) 1.1 3.7 16.3
Unannealed 0.6 1.6 3.1
300C/70%RH 0.6 1.6 3.1
300C/55%RS (ethanol); 300C/70%RH
(water) 0.6 1.7 3.2
Residual solvent content of the material from different batches
was also analyzed. Table 12 shows the residual solvent content of materials
from each batch as assessed by GC analysis. Residual solvent is partially
d using primary (ethanol) and secondary (water) conditioning. Material
that was treated using a secondary conditioning s exhibited increased
replacement of the IPA.
Table 12
Compound A Batches % IPA (w/w) % EtOH (w/w) % Water
Raw (un-milled) 4.7% 0.0% 3.1%
Unannealed 3.9% 0.2% 3.0%
300C/70%RH 3.6% 0.1% 3.4%
30C/55%RS; 300C/70%RH 2.1% 1.2% 3.4%
EXAMPLE 7
Compound A (IUPAC: 7-[(1 R)[2-[2-fluoro[[4-(2
isopropylthiazolecarbonyl)-1 -oxa-4,9-diazaspiro[5.5]undecan-9
yl]methyl]phenyl]ethylamino]-1 xy-ethyl]hydroxy-3H-1,3-benzothiazol-2
one; S,4R)-7,7-dimethyloxo-norbornanyl]methanesulfonic acid] salt)
was received with a 3.8% ethanol residual t. This material had been
previously micronized and conditioned according to the present description to
reduce the ce of isopropyl (IPA) and ethanol (EtOH) by solvent
exchange/removal. The material was d to another conditioning gas that
included water vapor, and was mixed with the conditioning gas in a conditioning
zone for imately 1.5 hours. As shown in Table 13, residual IPA and EtOH
was nearly completely removed and water content of the material increased.
Table 13
Micronized Compound A
Batch % IPA (w/w) % EtOH (w/w) % Water
As Received 0.1% 3.8% 3.1%
300C/70%RH (water) 0.0% 0.1% 3.6%
Claims (30)
1. A method of conditioning micronized crystalline les comprising: aerosolizing micronized lline particles within a delivery gas, wherein said micronized crystalline particles contain one or both of an amorphous material and a al solvent; continuously mixing the micronized crystalline particles with a conditioning gas comprising a carrier gas and a solvent vapor in a chamber; maintaining the aerosolized micronized crystalline particles in contact with the conditioning gas in a conditioning zone for sufficient time to result in annealing of said micronized crystalline particles, wherein said annealing results in one or both of reducing the presence of the amorphous material or reduction in the amount of residual solvent; and separating the micronized lline particles from the conditioning gas.
2. The method of claim 1, wherein the micronized crystalline particles are mixed with the conditioning gas for between about 0.1 to 600 seconds before they exit the ioning zone.
3. The method of claim 1, wherein the micronized lline particles are water soluble, the solvent vapor included in the ioning gas is an s solvent vapor, and the conditioning gas is provided at a temperature ranging from about 20 °C to 100 °C and at a relative humidity ranging from about 0.05% to 95%.
4. The method of claim 1, wherein ized crystalline particles are not water soluble, the solvent vapor included in the conditioning gas is an organic solvent vapor, and the conditioning gas is provided at a temperature g from about 20 °C to 100 °C and at a relative saturation of a non-aqueous solvent in the range of about 0.05% to 95%.
5. The method of claim 1, wherein micronized crystalline particles are an admixture of water soluble and non-water soluble materials, the t vapor included in the conditioning gas ses an aqueous solvent vapor and an organic solvent vapor, and the conditioning gas is supplied at a temperature ranging from about 10 °C to 100 °C and at a relative humidity of the aqueous solvent in the range of about 0.05% to 95% and relative saturation of the non-aqueous solvent in the range of about 0.05% to 95%.
6. The method of any one of the preceding claims, n the micronized crystalline particles are produced using a jet mill and are aerosolized in the jet mill gas flow.
7. The method of any one of the preceding claims, wherein the conditioning gas is mixed with the aerosolized micronized crystalline particles in a ratio of about 1 to 10 parts conditioning gas with about 1 part of the aerosolized micronized crystalline particles (volume/volume).
8. The method of any one of the preceding claims, wherein the conditioning gas is supplied at a flow rate ranging from about 25 rd cubic feet per minute (SCFM) up to about 300 SCFM while mixing with the micronized crystalline particles.
9. The method of any one of the preceding claims, wherein the aerosolized micronized crystalline particles is supplied at a flow rate ranging from about 25 standard cubic feet per minute (SCFM) up to about 200 SCFM while mixing with the conditioning gas.
10. The method of any one of the preceding claims, wherein the conditioning gas ses nitrogen gas.
11. The method of any one of the preceding claims, wherein the micronized crystalline les are mixed with the conditioning gas in a closed chamber.
12. The method of any one of the preceding claims, n the micronized crystalline particles comprise glycopyrrolate.
13. The method of any one of the preceding claims, wherein the micronized crystalline particles comprise budesonide.
14. A system for in-process conditioning of micronized crystalline particles comprising: a micronizing zone comprising a device for izing at least one crystalline material to form micronized crystalline particles; a mixing zone in fluid communication with the micronizing zone, n the micronized crystalline les are delivered from the micronizing zone to the mixing zone and n mixed with a conditioning gas; a ioning gas supply zone in fluid communication with the mixing zone, the conditioning gas supply zone providing the conditioning gas at a desired temperature and solvent vapor tration to the mixing zone to be mixed with the micronized crystalline particles; a conditioning zone in fluid communication with the mixing zone, wherein the mixture of the micronized crystalline particles and the conditioning gas is delivered and remains in the ioning zone for a desired residence time; and a separation and collection zone, wherein the conditioned micronized crystalline particles are separated from the conditioning gas and the conditioned ized crystalline particles are collected.
15. The system of claim 14, n the micronized crystalline particles are water soluble and the conditioning gas supply zone is configured to provide the conditioning gas at a temperature ranging from about 20 °C to 100 °C an d at a humidity ranging from about 0.05% to 90% relative humidity.
16. The system of claim 14, wherein the ized crystalline particles are not water soluble and the conditioning gas supply zone is configured to provide the conditioning gas at a temperature ranging from about 20 °C to 10 0 °C and at a relative saturation of a non-aqueous solvent in the range of about 0.05% to 90% in the flowing conditioning gas stream.
17. The system of claim 14, wherein the micronized crystalline particles are an admixture of water soluble and non-water soluble materials, and the ioning gas supply zone is configured to provide the conditioning gas at a temperature ranging from about 20 °C to 30 °C and at a relative humidity of 50 to 75% and a relative saturation of a nonaqueous solvent in the range of about 50% to 75% in the flowing conditioning gas stream.
18. The system of claim 14, wherein the conditioning gas supply zone is configured to provide the conditioning gas at a temperature of about 25 °C and with a humidity of about 65% relative humidity.
19. The system of claim 14, wherein the conditioning zone is configured to maintain the mixture of the micronized lline particles and the conditioning gas within the conditioning zone for a residence time of between about 0.5 to 60 seconds.
20. The system of claim 14, wherein the conditioning zone is configured to maintain the e of the micronized lline particles and the conditioning gas within the ioning zone for a residence time of between about 1 to about 10 seconds.
21. The system of claim 14 wherein the conditioning zone is configured to maintain the e of the ized crystalline particles and the conditioning gas within the conditioning zone for a residence time of about 3 seconds.
22. The system of claim 14, wherein the micronizing zone comprises a jet mill configured for izing the at least one lline material.
23. The system of claim 14, n the conditioning gas supply zone is configured to e the conditioning gas to the mixing zone at a flow rate ranging from about 150 standard cubic feet per minute (SCFM) up to about 300 SCFM.
24. The system of claim 14, wherein the micronizing zone is configured to deliver the micronized crystalline particles as an aerosolized particulate material to the mixing zone at a flow rate ranging from about 35 rd cubic feet per minute (SCFM) up to about 200 SCFM.
25. The system of claim 14, wherein the mixing zone comprises a sion head assembly, and wherein the conditioning gas and the micronized crystalline particles are mixed in the dispersion head assembly.
26. The system of claim 25, wherein the sion head assembly comprises a mixing head configured to control the mixing of the conditioning gas and the micronized crystalline particles.
27. The system of claim 26, wherein the mixing head comprises an injection nozzle inlet configured to deliver the conditioning gas to an injection , and wherein the mixing head comprises a delivery gas inlet configured to deliver the micronized crystalline particles to the injection nozzle, and wherein the injection nozzle is configured for mixing the conditioning gas with the micronized crystalline particles.
28. The system of claim 14, wherein the nce time in the conditioning zone of the mixture of the micronized crystalline particles and the conditioning gas is modified by ing the geometry of the conditioning zone.
29. The system of claim 14, n the residence time in the conditioning zone of the mixture of the micronized crystalline particles and the conditioning gas is modified by adjusting the rate at which the mixture of the micronized crystalline particles and the conditioning gas is delivered from the mixing zone to the conditioning zone.
30. The system of claim 14, wherein the separation and collection zone ses a cyclone collector. W0
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361799956P | 2013-03-15 | 2013-03-15 | |
US61/799,956 | 2013-03-15 | ||
PCT/US2014/029489 WO2014144894A1 (en) | 2013-03-15 | 2014-03-14 | Methods and systems for conditioning of particulate crystalline materials |
Publications (2)
Publication Number | Publication Date |
---|---|
NZ711200A NZ711200A (en) | 2020-09-25 |
NZ711200B2 true NZ711200B2 (en) | 2021-01-06 |
Family
ID=
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11471468B2 (en) | Methods and systems for conditioning of particulate crystalline materials | |
EP2560620B1 (en) | A process for particle processing of active pharmaceutical ingredients | |
Rehman et al. | Optimisation of powders for pulmonary delivery using supercritical fluid technology | |
HRP20050546A2 (en) | Preparation of sterile aqueous suspensions comprising micronised crystalline active ingredients for inhalation | |
EP1992335A1 (en) | Spray drying methods and compositions thereof | |
EP3346990B1 (en) | Jet milling method | |
EP1242048B2 (en) | INHALATION PARTICLES: method of preparation | |
EP1338273B1 (en) | Crystalline triamcinolone acetonide produced by a milling process | |
NZ711200B2 (en) | Methods and systems for conditioning of particulate crystalline materials | |
JP4085063B2 (en) | Inhalable powder containing CGRP antagonist BIBN4096 and method for preparing the same | |
Pietiläinen | Spray drying particles from ethanol-water mixtures intended for inhalation | |
WO2024121032A1 (en) | Process for producing lactose crystals, inhalable formulation | |
WO2003002111A1 (en) | Inhalation particles |